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Helicobacter pylori (H.pylori) was studied in duodenal
ulcer (DU) and gastric cancer patients.
The relationship between dietary linoleic acid, antral
H.pylori infection and DU was studied. A detailed dietary
history was obtained from DU patients and matched non-
ulcer dyspepsia controls. The fatty acid content of
abdominal adipose tissue biopsies was measured in both
groups. Levels of dietary and adipose tissue fatty acids
were related in controls and non-smokers. The adipose fatty
acids did not reflect dietary intake in DU patients or
controls who smoked. DU is associated with reduced adipose
tissue linoleic acid content and this is accentuated by
smoking.
In an in vitro test, linoleic acid was not shown to be
metabolised to more saturated fatty acids by H.pylori.
Eradication of H.pylori from the stomach prolongs
remission in DU disease but gastric re-infection is common
and leads to relapse. Tooth plaque was cultured from DU
patients and from matched controls. H.pylori was cultured
from the antrum in 89% and from tooth plaque in 19% of
duodenal ulcer patients. The identity of H.pylori was
confirmed by biochemical testing and DNA analysis. Some
strains were examined by electron microscopy. Ribotyping
II
showed that the organisms present in tooth plaque and the
antrum were identical but each individual carries a
separate strain. Gastric re-infection by H.pylori could
originate from dental plaque.
A general population of hospital inpatients with and
without teeth were studied by bacteriological culturing of
tooth plaque, by urease testing of tooth plaque and by
measuring plasma antibody to H.pylori. No significant
difference in antibody levels was found in either group.
In an in vitro experiments, bile acids inhibited or
prevented growth of H.pylori supporting the view that
biliary post-reflux gastritis and type B H.pylori gastritis
are of different aetiology.
Gastrectomy specimens from 83 patients who underwent
gastrectomy for primary gastric cancer and from 34 controls
who underwent gastric surgery for peptic ulcer were
reviewed histologically for H.pylori. No associations
were found between H.pylori and gastric intestinal
metaplasia, tumour extent or stage.
A cheap alternative "in-house" urea solution was
developed and is described. This is satisfactorily
sensitive and specific for the diagnosis of H.pylori and
could be used for epidemiological studies in field work.
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ABBREVIATIONS
BAO = Basal acid output
BRENDA = Bacterial restriction-endonuclease
digest-analysis
cAMP = Cyclic adenosine monophosphate
CLO = Campylobacter like organism
cm = Centimetre
DNA = Deoxyribonucleic acid
DU = Duodenal ulcer
duTP = Deoxyuridine triphosphate
EDTA = Ethylenediaminetetra-acetic acid
Fab = Antigen-binding fragment
FAME = Fatty acid methyl esters
FFA = Free fatty acid
GLC = Gas-liguid chromatography
gm = Gram
H2 = Histamine 2 receptors
HETE = Hydroxyeicosa tetraenoic
HLA = Human leucocytic antigen
HP = H.pylori (Helicobacter pylori)
Kg = Kilogram
KV = Kilovolt
LA = Linoleic acid
jiil = Microlitre










MUSFA = Monounsaturated fatty acid
NADH = Reduced nicotinamide adenine dinucleotide
NCTC = National collection of type cultures
nm = Nanometre
NSAID = Non-steroidal anti-inflammatory drug
OFN = Oxygen free nitrogen
PAO = Peak acid output
PG = Prostaglandin
PUSFA = Polyunsaturated fatty acid
QF = Quick fit
RFLP = Restriction fragment-length polymorphism
rpm = Revolutions per minute
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Peptic ulceration results from a break in the integrity
of the upper gastrointestinal tract mucosa. The ulcer
crater extends through the muscularis mucosae (Ivy et al.,
1950) and is surrounded by acute and chronic inflammatory
cells.
Peptic ulceration is a very common disease with serious
complications and great economic significance, and has
therefore been extensively studied. Despite this, its exact
pathogenesis is not yet known. Until 10 years ago study
of the cause and treatment of peptic ulceration
concentrated on the view that it resulted from either a
lowering of the defences in the mucosa or an increase in
digestive attack by acid and pepsin (Graham, 1989).
One of the most interesting findings during the past
decade has been that of the close association between the
bacterium Helicobacter pylori (H.pylori), type B gastritis,
and peptic ulceration. There are now strong grounds for
believing that peptic ulceration is, at least in part, an
infectious disease.
The work described in this thesis explores aspects of
peptic ulcer pathogenic factors and addresses the following
issues:
The relationship between dietary fatty acid intake and
duodenal ulcer; the capacity of H.pylori to metabolise
linoleic acid; a possible oral reservoir for infection of
the stomach by H.pylori; the prevalence of H.pylori in a
population of hospital inpatients; the influence bile acids
upon the growth of H.pylori; an exploration of the possible
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link between the presence of H.pylori and gastric cancer;
and the development of a simple, rapid urease test to
identify H.pylori.
1.1 THE EPIDEMIOLOGY AND CAUSES OF
PEPTIC ULCERATION - A REVIEW OF THE LITERATURE
1.1.1 EPIDEMIOLOGY
1.1.1.1 Prevalence
Epidemiological studies are made to elucidate patterns
of disease incidence and prevalence that may highlight
causal or protective factors. The first report of
prospective studies of the prevalence and epidemiology of
peptic ulceration appeared in 1950 (Ivy et al., 1950).
These showed considerable differences between and within
countries. Thus, the prevalence of active duodenal ulcers
(DU) found in Finland, by an endoscopic survey of 358
normal subjects, was 1.4% with a life-time prevalence of
5.9% (Ihamaki et al., 1979). The life-time prevalence in
American males is 10% and 4% for American females (Langman,
1979; Grossman, 1980). The yearly incidence of DU in
Denmark between 1963 and 1968 was 0.15% with a linear trend
of age-specific increase reaching 0.3% by the age of 75 to
79 years in males and 0.3% in females (Bonnevie, 1975).
The annual incidence of DU in Yorkshire, England, was
0.21% in males and 0.06% in females (Pulvertaft, 1959) and
in the United States was 0.08% in males and 0.04% in
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females (Kurata et al., 1985). DU is four times commoner
than gastric ulcer in the United States (Kurata et al.,
1984) .
1.1.1.2 Regional variation of peptic ulceration
There appears to be a real geographical variation in
the prevalence of DU. Its presentation, course and
complications also differ from country to country and
region to region (Pulvertaft, 1959; Langman, 1979; Tovey,
1979; Moshal et al., 1981; Hugh et al., 1984). The overall
prevalence of DU is higher in Scotland and (to a lesser
extent) in the north of England than in the south of
England (Langman, 1979) . DU is commoner along the west
coast of Africa than along the east coast, in northern
India than in the south, and amongst Chinese rather than
Japanese in Sumatra (Lam, 1989) . In Japan, gastric ulcer is
five to ten times commoner than DU (Sonnenberg, 1985).
1.1.1.3 Race and heredity
Data from different sources diverge over the importance
of race in predisposing to DU. DU prevalence,
hospitalisation and mortality are higher for whites than
for non-whites (Kurata and Haile, 1982). Age-specific
mortality rates indicate a somewhat higher mortality rate
from ulcer disease in non-whites than in whites up to the
age of 65, with the reverse being true at a more advanced
age (Kurata and Haile, 1982). Even with the limitations of
different data, there is little reason to suspect that race
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is a major predisposing factor for DU (Kurata and Haile,
1982) .
1.1.1.4 sex
DU is estimated to be 1.5 to 3 times commoner in males
than females (Pulvertaft, 1959; Bonnevie, 1975; Grossman,
1980 ) , but the prevalence of gastric ulcers is
approximately the same for men as for women (Ostensen et
al., 1985). The male to female ratio for DU has been
reported as 18:1 in India, 9:1 in Africa and in
Bangladesh, 4:1 in Hong Kong, 2:1 in the United Kingdom,
and 1:1 in the United States (Lam, 1989). The male to
female ratios for hospitalisation for DU and mortality
rates were respectively 1.8:1 and 2.4:1 in 1970. By 1983
both ratios had decreased to 1.3:1 (Kurata et al., 1985).
1.1.1.5 Changes in incidence and severity
The incidence and severity of peptic ulcer disease have
been declining for the past few decades (Hollander and
Tarnawski, 1986) and have also declined throughout the West
during this century (Mendeloff, 1974; Bonnevie, 1985). For
instance, there has been a gradual decline in the number of
hospital admissions for any reason associated with peptic
ulceration over the past few decades (Elashoff and
Grossman, 1980; Brown et al., 1976). This may reflect
decreasing incidence, change in the severity of the disease
or it may be due to revised criteria for admission;
nowadays peptic ulcer patients are mainly treated as
outpatients. There has been a decline in the incidence of
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perforated peptic ulceration (Mackay, 1966; Illingworth et
al. , 1944 ; Jamieson, 1955) . This is a good index of
severity because almost all the patients are hospitalised.
Most importantly, age-sex-specific death rates due to
peptic ulcer disease have also been declining during the
past few decades ( Susser, 1982; Kurata et al., 1983;
Sonnenberg et al., 1985).
A prospective study of first time diagnosed cases of DU
in males in New York city showed a significant fall over
the years 1952 to 1963 (Pulvertaft, 1959; Pulvertaft,
1968) . In Iceland, Jonasson et al. (1983) noted a less
marked decline.
The reasons for these falls in incidence, in severity
and in mortality have been widely studied, and many
hypotheses have been advanced to account for them (Friedman
et al., 1974; Langman, 1979; Kurata and Haile, 1984). One
aspect that has not been carefully considered is the
increased consumption of, and interaction between, dietary
essential fatty acids and the natural defence mechanisms of
the gastroduodenal mucosa (Hollander and Tarnawski, 1986) .
Other reasons for the decline include powerful new ulcer
healing drugs such as H2 receptor blockers, a decline in
smoking, a change in environment including
industrialisation, and changes in work patterns, and
climate (Kurata and Haile, 1984; Friedman et al., 1974).
Effective ulcer healing drugs have been available since
the late 1970's and their use has been associated with a
marked fall in the number of operations performed for
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uncomplicated peptic ulcer. These drugs do not affect the
development of an ulcer but they do induce temporary
remissions. However, the falling incidence of peptic ulcer
disease pre-dated the introduction of these new agents.
1.1.2 CAUSES OF PEPTIC ULCERATION
In gastric ulcer patients, acid and pepsin secretion
are often normal or lower than normal. By contrast, DU is
more closely related to greater acid and peptic activity
(Baron, 1970). Peptic ulceration can be seen as the
consequence of imbalance of defence and attacking forces.
1.1.2.1 Mucosal Defence
Many defences (fig. 1.1) resisting attack by acid and
peptic activity have been described and are reviewed below,
drawing from the reports published by Allen et al., 1988;
Hudson et al., 1990; Mertz et al., 1991; and Zandomeneghi
et al., 1991. Defence mechanisms include: a) a barrier
preventing contact between the mucosa and luminal contents,
formed by an adherent mucus (gel) layer of normal
viscosity, and bicarbonate secretion by the mucosa; b)
normal cellular integrity and resistant lipoprotein /
phospholipid membrane of epithelial cells; c) vascular
integrity maintaining a proper blood supply to the mucosa;
d) adequate cell replication in the mucosal crypts, normal
mucosal regenerative capacity and cell turnover; e)
epidermal growth factor; f) normal levels of locally













Fig. 1.1 Pathophysiology of duodenal ulcer
-aggressive and defensive factors-
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prostaglandins (PG). It is believed that the mucosal
defences may be breached and peptic ulceration follow if
any of these are deficient.
1.1.2.1a The mucus barrier
A 180 jum thick adherent layer of water-insoluble
mucus gel forms a continuous cover over the gastroduodenal
mucosal surface and is the first line in the mucosal
defence against acid and pepsin. This gel provides a stable
layer that supports surface neutralisation of acid by
mucosal bicarbonate secreted from the mucosa and is a
diffusion barrier to pepsin, so preventing proteolysis of
the underlying epithelial cells. Mucosal viscosity is also
maintained by the secretion of new mucus by epithelial
cells. The mucus gel does not provide a significant
diffusion barrier to hydrogen ions (Allen et al., 1988;
Freston, 1989).
1.1.2.1b Cell layer integrity and lipoprotein membrane
The luminal surfaces of the mucosal cells are connected
by a trilaminar lipoprotein membrane which forms a major
defence barrier. The basement membrane on which the cells
rest is also a barrier. The integrity of the layer of cells
is essential to mucosal defence (Bardhan, 1981).
1.1.2.1c Gastric mucosal blood supply
Gastric mucosal blood flow and ischaemia are important
in the pathogenesis of acute mucosal injury. An adequate
blood flow maintains the secretory and metabolic activity
of the cells and facilitates removal of hydrogen ions that
have diffused back into the mucosa (Whittle, 1977; Guth,
1982). Taha et al. (1991) reported that duodenal, but not
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gastric mucosal, blood flow is reduced in nonsteroidal
anti-inflammatory drugs users who smoke and patients with
DU or H.pylori.
1.1.2.Id Gastric mucosal cell replication
Gastric epithelial cells normally survive for only two
to six days and therefore need to be constantly replenished
by new cells which arise from the neck of the gastric
glands. Any interference with cell replication and
maturation weakens mucosal defence (Bardhan, 1981).
1.1.2.1e Epidermal growth factor (EGF)
Epidermal growth factor is a polypeptide found in a
number of body fluids, including saliva and
gastrointestinal secretions. It inhibits gastric acid
secretion, accelerates cell maturation, stimulates
cellular proliferation and increases PG synthesis (Itoh
et al. , 1988 ; Konturek et al. , 1989 ; Freston, 1989 ;
Zandomeneghi et al., 1991).
1.1.2.If The protective role of prostaglandins
The existence of PGs was demonstrated by Kurzok (1930)
when he noted that strips of uterus relax or contract when
exposed to semen. Bergstrom and Sjoval (1960) isolated PGs
in a pure form and later defined their chemical structure.
PGs are synthesised by the gastroduodenal mucosa from the
biological precursors the polyunsaturated fatty acids,
linoleic acid and arachidonic acid (Pesker, 1977). Linoleic
acid and arachidonic acid are released from membrane bound
phospholipids (fig. 1:2) by the action of phospholipase A 2










Thromboxane A,, Prostacyclin (PGI2)
Fig. 1.2 Arachidonic acid metabolism. Arachidonic acid is converted by cyclo-
oxygenase to cyclic endoperoxides which are then converted by tissue
enzymes to prostaglandins. Vascular endothelium synthesizes a
prostaglandin with a different structure, prostacyclin (PGI2).
Platelet enzymes produce thromboxane A2. Leucotrienes are important
regulators of inflammatory and hypersensitivity reactions.
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hormonal factors. Arachidonic acid is rapidly metabolised to
oxygenated products by the cyclo-oxygenase and lipoxygenase
pathways. The intermediate cyclo-oxygenase products are
converted to PGs, the lipoxygenase products to leukotrienes
(fig. 1.2).
There are four groups of such substances, cyclic
compounds and the prostanoids which include the PGs,
prostacyclins and thromboxanes.
The prostanoids are cyclic hydroxy fatty acids with two
side chains one of which carries a carboxyl group, the
other a hydroxy group at C 15. They are very potent
biologically and are important local hormones generated in
situ, rapidly metabolised and are briefly active in the
immediate vicinity of their synthesis.
PGs (fig. 1.3) and prostacyclins have a cyclic ring of
5 carbon atoms, whilst thromboxanes have a ring of 6 carbon
atoms. They have potent effects on smooth muscle, platelet
stickiness and blood vessel contractility. Prostacyclins
(vessel wall constituents) inhibit platelet stickiness,
relax arterial wall tone, and decrease systemic blood
pressure. Thromboxanes (platelet constituents) by contrast
cause platelets to clump, increase arterial wall tone and
increase systemic blood pressure.
The chemical nomenclature is based on the fully
saturated 20-carbon acid with Cg to C12 closed to form a
five membered ring prostanoic acid. There are different
classes - the suffices A, B, C, D, E, F, G, H denote
different constituents of the ring and the numerical

































Fig. 1.3 Structure of prostaglandins
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the side chain. The difference between the E and F series
lies in the keto and hydroxyl groups at position 9
respectively.
As shown in fig. 1.3, the precursor of the prostanoids
(eicosanoids) is arachidonic acid, which can fold and allow
the appropriate groups to come into juxtaposition for the
ring to close. This occurs in the microsomal fraction and
is catalysed by prostaglandin endoperoxide synthetase, a
multifunctional protein. This enzyme inserts 2 molecules of
oxygen to yield a 15- hydroperoxyl-p, endoperoxide with a
substitute cyclopentane ring PGG. This is a cyclo-oxygenase
activity of the enzyme. A peroxidase activity reduces PGG
to its 15-hydroxy analogue. Free radical intermediates
inactivate the enzyme as do certain nonsteroidal anti¬
inflammatory drugs, e.g., aspirin or indomethacin. These
drugs compete with the fatty acid substrate for the cyclo-
oxygenase active site. Aspirin also acetylates a serine
hydroxyl at or near the active site which permanently
inactivates the enzyme. The acetylenic fatty acids such as
eicosa-5,8,11,14 tetraenoic also have the same effect.
The range of eicosanoids is considerable and their
effect varies from tissue to tissue. The various
eicosanoids are found throughout the whole of the
biological system. They inhibit platelet aggregation,
increase platelet cAMP content, affect membrane receptors,
act as peripheral vasoconstrictors, pulmonary
vasoconstrictors and bronchoconstrictors. PGE2 reduces ADH
production and alters water reabsorption and controls renin
release and thus influences kidney function.
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Thromboxane (TX) A2 is labile, has a short half life
and is converted into TXB2• TXA2 influences platelet
aggregation. Leukotrienes are epoxy fatty acids active in
respiratory, vascular and intestinal smooth muscle. Three
lipoxygenases (5-,12-,15-) have been found in mammalian
tissue. 5 lipoxygenase is important in leukotriene
production in neutrophils, eosinophils, monocytes, mast
cells, keratinocytes and lungs, spleen, brain and heart.
Products of 12 lipoxygenase activity inhibit collagen
induced platelet aggregation. The biological relevance of
15 hydroxyeicosatetraenoic (HETE) is unknown. Leukotrienes
have potent biological functions. The peptido-leukotrienes
cause constriction of bronchi, especially small airways.
They also have microvascular effects on arteriolar
constriction, venule dilatation and plasma exudation. They
are chemotactic agents for neutrophils, eosinophils and
also are involved in the contraction of small
gastrointestinal smooth muscle.
After linoleic acid is absorbed from the
gastrointestinal tract it is converted into longer chain
fatty acid in the liver e.g., di-homo-gamma-linoleic acid
(fig. 1.4), and then stored as a tri-acy1-glyceride. In
man, arachidonic acid is by far the commonest and gives
rise to the series II PGs. It is either derived from
linoleic acid or ingested itself. It is esterified and
stored as tri-acy1-glycerides throughout the body as a
component of phospholipids in cell membranes. The first
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Fig. 1.4 Prostaglandin pathway
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esters or is an activation of the release of arachidonic
acid from the 2 position o-phosphoacylglycerides. The
important phospholipids are those which are a source of
arachidonic acid phosphatidylcholine and phosphoinositides.
Only those fatty acids capable of being converted into the
delta -5,8,11,14 tetraenoic fatty acids of chain length
19,20,22 are essential because these give rise to
physiologically active eicosanoids. Eicosanoids are
metabolised very rapidly and are excreted in urine or bile.
There is a great divergence between the 10 gm of essential
fatty acid which are thought to be necessary in the diet
and the 1 mg of PG metabolites formed per 24 hours in man.
The released fatty acids are adsorbed to plasma albumin
to be taken to other tissue for metabolic utilisation by
beta-oxidation pathways. The determinant of beta oxidation
or acyl glycerol synthesis is dictated by available acyl-
CoA molecules by the acyl transferase and the carnitine
palmityl transferase of the mitochondrial membrane. This
latter is increased during starvation. The n-6 unsaturated
fatty acids, linoleic and arachidonic acid, give rise to
the 3-series and 4-series leukotrienes respectively,
whereas the alpha-linoleic acid n-3 of fish oil origin
gives rise to the 5-series leukotrienes. Linoleic acid and
arachidonic acid give rise to the 1 and 2 series PGs
respectively whereas alpha-linoleic acid gives rise to the
3 series. The relative contribution of n-3 and n-6 fatty
acids in the diet will, therefore, dictate the spectrum of
types and biological potencies of the prostanoids and
leukotrienes.
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Other than this dietary control, the production of
eicosanoid formation is dependent upon phospholipase A2
activity. This activity is activated and inhibited by a
number of messengers in a similar manner to the inositol
cyclase system.
In man, the most prominent PG in the gastrointestinal
tract is PGE (Bennett et al., 1968). When linoleic acid or
arachidonic acid is administered intragastrically, the
concentration of PG in the stomach rises several
thousandfold within a matter of minutes (Hollander et al.,
1982), promoting mucosal protection and accelerating the
repair of mucosal ulceration (Robert et al., 1979;
Hollander et al., 1982; Tarnawski et al., 1985). Evidence
is accumulating that endogenous elaboration of PG, mainly
of the PGE group, by the gastroduodenal mucosa is of great
importance in the intrinsic defence against ulceration
(Hollander et al., 1982). These PGs, administered
exogenously (Robert et al., 1979) or synthesised
endogenously (Hollander et al., 1982), can prevent mucosal
ulceration induced experimentally by aspirin, alcohol, bile
acids, and even boiling water (Hollander et al., 1982).
Lack of linoleic acid in the diet and consequently in
the gastric mucosa results in a decrease of PGE to the
extent that gastric mucosal protection is no longer
sufficient to maintain the integrity of the mucosal
barrier; consequently, DU follows (Grant et al., 1988 and
1990). These workers have also shown that the linoleic
acid content of adipose tissue in DU patients was
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significantly lower than that of control subjects.
It has been suggested that H.pylori could metabolise
gastric polyunsaturated and monounsaturated fatty acid to
saturated fatty acids and consequently, by reducing PG
production cause a lowering of the gastric mucosal barrier
and increase the likelihood of peptic ulceration.
(Experiments designed to test this theory are described in
chapter 4 of this thesis).
PGs are, therefore, important for cytoprotection (fig.
1.5), or more properly and appropriately, "gastric mucosal
protection". This involves many mechanisms ( Robert, 1981;
Miller, 1983; Hollander and Tarnawski, 1986; Malagelada et
al., 1986; Rask-Madsen and Lauritsen, 1987; Hawkey, 1989;
Tovey et al., 1989; Northfield and Goggin, 1991) including:
the maintenance of an intact mucosal barrier by increasing
mucosal blood flow (Jacobson, 1986; Wilson, 1991);
production of adherent mucus gel; increase in mucus
viscosity; increase in the hydrophobicity of the mucus
layer; increased mucus output (Johansson and Kollberg,
1978; Bolton et al., 1978; Wilson, 1991); increased
bicarbonate output (Feldman, 1983; Isenberg et al., 1986,
Wilson, 1991); increased cell turnover; increased
macromolecular synthesis; providing cellular protection by
increasing cAMP in the sodium pump. PGE in the stomach
also inhibits acid secretion (Befrits and Johansson, 1985).
This occurs whether the PG is given intravenously or orally
(Horton et al., 1968; Classen et al., 1971).
Pharmacological analogues of PGs, for instance arbaprostil







Fig. 1.5 Modes of action of prostaglandin E
on the gastric mucosa
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intravenously or orally (Konturek et al., 1976).
It is possible that an increase in the intake of
polyunsaturated (linoleic acid) and mono-unsaturated fatty
acid in the diet could result in greater production of PGs
by the gastric mucosa with a consequent increase in the
gastric mucosal defences and a corresponding lowering of
the risk of peptic ulceration. Long term dietary fatty acid
intake is said to be reflected in the fatty acid levels in
the adipose tissue of an individual (Wood et al., 1987).
In chapter 3 of this thesis the relationship between the
essential fatty acid levels in the diet and in the adipose
tissue of DU patients and control subjects is examined.
1.1.2.2 Attack upon the mucosa
The attack (see fig. 1.1) upon the mucosa is a
combination of acid and pepsin secretion. The following
factors (Soil and Berglindh, 1987; Graham, 1989) might be
important: a) increased parietal cell mass and increased
chief cell mass; b) increased basal acid secretory drive;
c) increased postprandial acid secretory drive; d) rapid
gastric emptying; e) abnormalities of motility and
duodenogastric reflux; and f) type B (H.pylori) gastritis.
1.1.2.2a Increased parietal cell mass and chief cell mass
The maximum capacity of the stomach to secrete acid
(maximal acid output or MAO) is a function of the total
parietal cell mass (Grossman and Elashoff, 1980; Lam, 1984)
which is 1.5 to 2 times greater in DU patients than in
control subjects. The values for normal subjects and DU
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patients overlap, and only between 20 and 50 per cent of DU
patients hypersecrete acid (Cox, 1952). Approximately two-
thirds of DU patients also have an increased blood level of
pepsinogen 1 (Samloff et al., 1975).
1.1.2.2b Increased basal acid secretory drive
Basal acid output (BAO) varies with total acid
secretory capacity, and therefore, might be increased in
subjects with an increased MAO. By determining the ratio of
BAO to MAO or peak acid output (PAO) and making adjustments
for the variable gastric parietal cell number, an
elevated BAO / PAO ratio suggests an increased basal
secretory drive. Most investigators consider a BAO / PAO
ratio above 0.3 to indicate an increased basal secretory
drive (Feldman et al., 1980; Kirkpatrik and Hirschowitz,
1980; Lam, 1984; Blair et al., 1987).
The physiology of acid secretion is complex, and the
parietal cell is regulated by input from endocrine, neural,
and paracrine pathways; gastrin, acetylcholine, and
histamine are the primary respective chemotransmitters
delivered by these pathways. Increased activity of any of
these pathways might increase basal secretory drive in DU
patients (Soil and Berglindh, 1987) .
1.1.2.2c Increased postprandial acid secretory drive
This might be due to postprandial hypergastrinaemia,
decreased acid inhibition of postprandial gastrin response
or increased parietal cell sensitivity to gastrin.
Increased postprandial acid secretory drive was found in
about 10% of the DU patients in one study, but the
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pathophysiological significance of this abnormality has not
yet been established (Cooper et al., 1985).
Impaired acid inhibition of gastrin release has been
proposed to explain the enhanced gastrin release found in
some DU patients, but this has not yet been confirmed
(Walsh and Grossman, 1975; Malagelada et al., 1977; Cooper
et al., 1985) .
Gastrin, which is elaborated by antral mucosal
endocrine cells (G cells), is a trophic hormone but its
main function is to stimulate acid production. It also
stimulates growth of parietal cells when its concentration
in the circulation is excessive (Walsh et al., 1975). If
the pH of the antral contents is lowered to 2.5, gastrin
release is almost totally inhibited in normal subjects but
only moderately reduced in DU patients (Walsh et al.,
1975). Basal or postprandial hypersecretion of acid results
from an enhanced sensitivity of parietal cells to
secretagogues. At least some DU patients are more sensitive
to both exogenous gastrin infusion and to endogenously
released gastrin than are control subjects (Lam et al.,
1980; Lam and Koo, 1985). Increased sensitivity to gastrin
in DU patients probably follows enhanced vagal tone, an
altered affinity of the parietal cell receptors for
gastrin and an impairment of an inhibitory pathway, such as
that mediated by somatostatin. This hypothesis is disputed
by others (Hirschowitz, 1984).
Gastric secretion is stimulated primarily by the act of
eating. Two mechanisms are involved: first, via the vagus
by direct cholinergic action on parietal cells; and,
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second, by indirect action through the release of several
peptides such as gastrin, somatostatin and bombesin
(Tache, 1988). The sight and smell of food lead to modest,
vagally mediated secretion by the stomach, but chewing and
swallowing food provide a particularly powerful vagal
stimulus. Gastrin interacts with the vagus at the receptor
site to stimulate powerful secretion of gastric juices.
There are receptors (histamine, muscarinic, cholinergic and
gastrin receptors) on the parietal cell for vagal and
humoral stimuli. These stimuli act largely through
histamine (probably produced by mast cells) to provide the
final stimulus to the parietal cell (Colin- Jones, 1986;
Colin-Jones, 1987) .
1.1.2.2d Rapid gastric emptying
A meal evokes acid secretion, but in normal subjects
the food stays long enough in the stomach to buffer the
acid produced. In contrast, in DU patients rapid gastric
emptying removes the food, leaving the acid unbuffered, so
that an abnormally large acid load is delivered into the
duodenum (Howlett et al., 1976; Graham, 1989).
1.1.2.2e Gastroduodenal motility disorder and
duodenogastric reflux
Motility defects are mainly found in relation to
gastric ulcer. An incompetent pyloric sphincter might allow
reflux of duodenal contents into the stomach causing
gastritis and gastric ulcer. Delayed gastric emptying,
perhaps due to antral hypomotility, may lead to stasis and
delayed clearance of refluxed duodenal contents. Duodenal
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contents might injure the gastric mucosa by damaging the
gastric mucosal barrier leading to increased hydrogen ion
back diffusion. If emptying is delayed, food is retained
in the antrum; this could lead to increased gastrin release
and greater acid secretion (Burge, 1966; Dragstedt and
Woodward, 1970). Acid delivered into the duodenum is
neutralised by pancreatic bicarbonate. In patients with DU,
because the frequency of duodenal contractions is reduced,
acidity in the proximal duodenum is not adequately reduced
enhancing the risk of duodenal ulceration (Borgstrom and
Arborelins, 1978).
1.1.2.2f Type B (H.pylori) Gastritis
This is described in detail later on in this chapter
under the heading of H.pylori and peptic ulceration.
1.1.2.3 Other risk factors for peptic ulceration
Additional risk factors include: a) cigarette smoking;
b) diet and drinks; c) alcohol; d) drugs (nonsteroidal
anti-inflammatory drugs and aspirin); e) corticosteroids;
f) occupation; g) socioeconomic status; h) familial
aggregation, blood group and tissue antigen; i) psychology
and personality type; j) mental stress.
1.1.2.3a Cigarette smoking
Cigarette smoking appears to be a risk factor for the
development, maintenance, and recurrence of peptic ulcer
disease (Freston, 1989). Smoking has an inconsistent effect
on gastric acid secretion, but it does have other effects
on upper gastrointestinal function which could contribute
to the pathogenesis of peptic ulcer disease. These include
25
( Solomon and Jacobson, 1972; Eastwood, 1988; Hudson et
al., 1990): the inhibition of mucosal PG synthesis by
interfering with the cyclo-oxygenase pathway; decreased
pancreatic and duodenal bicarbonate secretion; increased
gastric emptying; increased duodenogastric reflux; decreased
gastric mucus secretion; decreased gastric blood flow;
decreased secretion of salivary epidermal growth factor
(Hixson et al., 1987); increased gastrin. Smoking also
interferes with the action of histamine-2 antagonists
(Eastwood, 1988; Hudson et al., 1990; McCready et al.,
1985) .
There is a positive correlation between the guantity
of smoking and peptic ulceration (especially for DU)
(Friedman et al., 1974; Harrison et al., 1979; McCarthy,
1984). Cigarette smoking is associated with decreased
ulcer healing (Sontag et al., 1984), high DU recurrence
rates and increased DU complications. Whether smoking is
associated with ulcer development remain unclear but
smoking increases the risk of DU in subjects who are
infected with H.pylori (Martin et al., 1989).
Recently, a defect in ventilatory function has been
found in patients with chronic gastric ulcer and to a
lesser extent in patients with DU (Kellow et al., 1986;
Stemmermann et al., 1989). The defect in gastric ulcer
patients was more severe in smokers than in non-smokers.
Whether smoking led to the ventilatory defect, which in
turn led to ulceration, or whether there was simply an
association with smoking, ventilatory defects and gastric
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ulcer is not known (Dippy et al., 1973). Death rates from
ulcer disease are greater in patients who smoke, although
it is not clear whether this apparent increase in mortality
reflects more severe ulcer disease or the cardiac and
pulmonary consequences of smoking (Harrison et al., 1979).
Aspects of the relationship between cigarette smoking
and linoleic acid content in the adipose tissue of
duodenal ulcer patients and controls have been examined in
this thesis in chapter 3.
1.1.2.3b Diet and drinks
Although certain foods, beverages and spices may cause
dyspepsia, there are no data to show convincingly that
specific substances in the diet cause, perpetuate or
reactivate DU. Some studies suggest that increasing
dietary fibre reduces DU incidence and recurrence rates
whilst other studies show the opposite (Malhotra, 1978;
Langman, 1979, Tovey, 1979, Rydning and Berstad, 1986;
Holcombe, 1992). Marotta and Floch (1991) reported that
"vitamin U" found in cabbage and in green vegetables helps
peptic ulcer healing. Spices have long been implicated as
a cause of gastric mucosal injury. Myers et al. (1987)
showed that there is no significant effect of capsaicin,
red or black pepper on gastric mucosa. Tovey et al. (1989)
reported that black tea without milk and sugar resulted in
an increased acid output which was more pronounced with DU
patients. Coffee (Cohen, 1980), tea (Dubey et al., 1984),
and other, non-caffeine containing beverages (McArthur et
al., 1982) greatly stimulate acid secretion but have not
yet been proven to be a cause of peptic ulceration.
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A statistically significant relationship has been found
between salt consumption, urinary sodium chloride excretion
and death rates from gastric ulcer disease in several
countries (Sonnenberg, 1986). Recently, evidence has begun
to accumulate to suggest that increasing the amount of
linoleic acid in the diet protects against the development
of peptic ulceration (Grant et al., 1988 and 1990).
1.1.2.3c Alcohol
Alcohol in high concentrations causes upper
gastrointestinal mucosal erosions, gastritis and bleeding.
These acute effects do not appear to progress to chronic
peptic ulcer, and alcohol was not found to be a risk
factor for DU (Friedman et al., 1974; Paffenbarger et al.,
1974). The extent to which alcohol by itself stimulates
acid secretion in man is controversial. A standard test
meal used to consist of 50-100 ml of 10% ethanol in water.
There is, however, no doubt that wine, beer and other
alcoholic beverages are acid secretagogues (Lenz et al.,
1983; Peterson et al., 1986), probably due to components
other than alcohol.
1.1.2.3d Drugs (nonsteroidal anti-inflammatory drugs -
NSAIDs and aspirin)
Some studies (Gillies and Skyring, 1969; Levy, 1974,
Cameron, 1975; Bugat et al., 1976; Piper et al., 1981)
suggest an association between treatment with aspirin or
other NSAIDs, chronic ulceration and peptic ulcer
bleeding. Hawkey, (1990), in a review article concluded
that aspirin and other NSAIDs cause chronic gastric
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ulceration. NSAIDs consumption has been firmly associated
with the development of gastric ulcers, but the association
with DU remains controversial (Levy, 1974; Piper et al.,
1981; Freston, 1989). In the elderly, i.e.. over 60 years
of age, NSAID consumption is a risk factor for bleeding
from both DU and gastric ulcers (Somerville et al., 1986).
Damage from aspirin and NSAIDs in the upper
gastrointestinal tract is probably dose-dependent.
Tarnawski et al. (1990) showed that aspirin and NSAIDs
damage both superficial and deep gastric microvessels with
a 71% reduction of healthy mucosal cells and also cause
increased vascular permeability, stasis, mucosal oedema and
release of inflammatory mediators.
There are at least two mechanisms whereby aspirin and
other NSAIDs might cause mucosal damage. First, aspirin
alters ion transport and the potential difference across
the gastric mucosa (Davenport, 1964 and 1966). Secondly,
NSAIDs inhibit PG synthesis (Whittle, 1981; Ligumsky et
al., 1982). Thus, NSAIDs have been shown in animal models
to reduce both epithelial bicarbonate secretion (Rees et
al., 1983), mucus synthesis and secretion (Menguy and
Masters, 1965; Rainsford, 1978), resulting in a reduced pH
gradient across the mucus gel layer and exposure of
epithelial cells to a more acidic environment (Ross et al.,
1981; Flemstrom and Kivilaakso, 1983). NSAIDs may augment
acute inflammation caused by H. pylori, and inflammation
can exacerbate the biochemical injury to these tissues
caused by NSAIDs (McCarthy, 1991).
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1.1.2.3e Corticosteroids
The effect of corticosteroids is controversial, but
one study suggests that there is an increased risk of
peptic ulceration following the administration of
corticosteroids for more than 30 days or in a total dose
greater than 1 gm of prednisolone (Conn and Blitzer, 1976).
This risk was not substantiated by another study (Messer et
al., 1983).
1.1.2.3f Occupation
Despite the belief that DU is more likely to affect
highly stressed professional and executive workers, the
available evidence suggests that, if anything, DU is
slightly commoner among unskilled labourers (Pulvertaft,
1959; Langman, 1979).
1.1.2.3g Socioeconomic status
Data from the National Health Survey in the United
States (1979) suggest an inverse relationship between
peptic ulcer and family income. In one study, DU was
commoner among persons of low educational achievement, an
effect partly accounted for by their smoking more
cigarettes (Friedman et al., 1974).
1.1.2.3h Familial aggregation, ABO blood group and HLA
antigen
Some workers have recognised a familial aggregation of
DU, but the patterns of inheritance are complex (Rotter and
Rimoin, 1977) . In some reports 20 to 50 per cent of DU
patients have a family history of DU, compared to 5 to 15
per cent of non-ulcer subjects (McConnell, 1980; Rotter,
30
1983). The familial aggregation of both DU and gastric
ulcers is distinct; the first degree relatives of patients
with DU had a threefold increase in the prevalence of DU
but not of gastric ulcer. In contrast, relatives of
patients with gastric ulcer had a threefold increase in the
prevalence of gastric ulcer but not of DU (Doll and
Kellock, 1951). Twin studies showing that concordance of
peptic ulceration is commoner in monozygotic than in
dizygotic twins indicates the existence of genetic factors
(McConnell, 1980; Rotter, 1983). Individuals with blood
group 0 have about a 30% greater risk of DU, compared with
individuals with blood groups A, B, or AB. Individuals who
are not secretors have a 50% greater risk of DU, while
individuals who are both blood group 0 and H-substance
non-secretors have 150% greater risk (McConnell, 1980;
Rotter, 1983), i.e.. the risk with both genetic markers is
more than additive. In addition, DU is commoner in
Caucasians with tissue type HLA-B5 than in controls
(Rotter, 1983). HLA-B12 phenotypes are found in greater
frequency (Ellis and Woodrow, 1979) with DU.
1.1.2.3i Psychology and personality type
There is a specific "ulcer" personality characterised
by an exaggerated dependency-independency conflict. Peptic
ulcer patients can display exaggerated self-sufficiency,
driving ambition, or aggressiveness. Certain traits
including hypochondriasis, lowered ego strength, and
excessive dependency (Feldman et al., 1986) are commoner in
peptic ulcer patients than in controls. Dependency, anxiety
and neurotic tendencies are found more commonly amongst
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ulcer patients (Magni et al., 1986).
1.1.2.3j Mental stress
Both patients and physicians believe that peptic ulcer
disease often get worse during or after stressful life
events. Occupational, educational, or financial problems or
family illness often precede the development or recurrence
of DU (Meikle et al., 1976). Whilst there is some evidence
to suggest that stress is causally related to ulcer disease
and its complications (Stewart and Winser, 1942), this is
difficult to prove because the definition and
quantification of stress is itself difficult (Rabkin and
Struening, 1976). The important variable is probably not
the intensity of external stress, but rather the
individual's interpretation and reaction to the stress
(Feldman and Sabovich, 1980). Anxiety, resentment, guilt,
and feelings of humiliation might increase acid secretion
through cholinergic mechanisms. A patient's mental state
might not only alter BAO, but also might alter the
sensitivity of parietal cells to exogenous stimulation.
1.2 Helicobacter pylori AND PEPTIC ULCERATION
During the past decade, it has become clear that there
is a close inter-relationship between infection with the
bacterium H. pylori , type B antral gastritis and DU.
H.pylori is a slender, curved, spiral gram-negative,
microaerophilic rod, approximately 2.5-2.9 pm in length and
0.5-0.85 pm diameter with a smooth coat and four to six
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unipolar unsheathed flagella with terminal bulbs and a
divergent 16S rRNA sequence. It has no axial filaments. The
enzymes urease, catalase, oxidase and alkaline phosphatase
are present in this organism (Itoh et al., 1987; Warren and
Marshall, 1983; Tytgat, 1987; Andersen et al., 1987).
That spiral bacteria can be found in the stomach has
been known for a hundred years. Bizzozero in 1893 first
described spiral microorganisms in the gastric mucosa of
dogs. Krienitz in 1906 found spiral bacteria in the gastric
contents of patients with ulcerating gastric cancer. He
also found "spirochaetes" in 14% of patients with gastric
ulcer in the same year, but little attention was paid to
this finding. Doenges (1939) described several types of
spiral organisms in 43% of 242 stained human stomach
autopsy specimens. Freedburg and Barron (1940) found
"spirochetes" in 54% of patients with gastric ulceration.
These findings led to speculation about a possible
pathogenic role of these spiral bacteria in peptic ulcer
disease (Freedburg and Barron, 1940) but did not provide
any evidence to corroborate such a suggestion. Steer and
Colin-Jones (1975) observed Gram-negative bacteria under
the mucus layer in 80% of 47 patients with gastric ulcer.
The present upsurge of interest in the role of H.pylori
in peptic ulceration can be dated to 1983 when Warren and
Marshall (1983 and 1984) in Australia observed curved and
S-shaped bacilli (then named Campylobacter pylori and
subsequently renamed Helicobacter pylori by Goodwin et
al., 1989) in endoscopic antral mucosal biopsies of
patients with gastritis and peptic ulcer. Marshall et al.
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(1985) showed that ingestion of 10 colony-forming units of
Campylobacter pylori led to an active inflammatory reaction
in previously normal gastric mucosa thus fulfilling Koch's
third and fourth postulates, i.e.. that "the inoculation
of germs obtained from the disease and grown in pure
culture should produce the same disease in a susceptible
animal and should be found thereafter in the diseased
areas so produced in the animal".
Volunteers who ingested H.pylori remained symptom free
for 3 to 7 days. Thereafter half of them experienced
epigastric discomfort, nausea and vomiting with or without
halitosis. The remainder were asymptomatic. This suggested
that if the normal immune processes did not clear the
infection, then mild gastrointestinal disturbances might
persist, and the patient could develop achlorhydria. They
found that hypo- or achlorhydric phase lasted 3 to 12
months, during which time the histological pattern of
active chronic gastritis developed; polymorphonuclear
leucocytes in the mucosa gradually being replaced by
lymphocytes and plasma cells. As immunity increased, the
inflammation in the corpus region decreased and acid
secretion returned to normal. The most severely affected
mucosa was in the antrum and pyloric canal possibly because
bacterial growth is less inhibited by acid secretion.
Marshall et al. speculated that at this stage the
development of peptic ulceration may be likely, because
the inflamed mucosa is probably more vulnerable to acid.
H.pylori also affects the islands of metaplastic gastric
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epithelium found in the duodenum, and by weakening the
normal defence mechanisms of the cell against acid attack
mucosal integrity is disrupted and DU occurs (Marshall et
al., 1985).
A prospective study in Amsterdam showed that
Campylobacter pylori like organisms are the causative
factors of gastritis, gastric and duodenal ulcers and non-
ulcer dyspepsia syndrome (Rauws and Tytgat, 1989).
1.2.1 EPIDEMIOLOGY OF H.pylori
H.pylori has been commonly isolated from the stomachs of
diverse populations throughout the world (Cover et al.,
1989). Although most studies have focused on the presence
of H.pylori in the stomach of symptomatic persons, the
organism has commonly been isolated from asymptomatic
subjects (Blaser, 1987) . The organism has been identified
by culture, silver staining or both in material from the
stomach of patients with histological gastritis at a
frequency ranging from 62% to 97% (Yeomans, 1988).
Serological and histological studies have been used in
most population studies (Rautelin and Kosunen, 1991). An
age-dependent increase in antibodies against H.pylori is
well recognised (Jones et al., 1986; Morris et al., 1986b;
Perez-Perez et al., 1988; Kosunen et al., 1989; Megraud et
al., 1989; Sitas et al., 1991). In developed countries the
presence of H.pylori infection seems to be low in children.
It gradually increases with age, from 10% in young adults
to reach a peak of 70% by the eighth decade (Rautelin and
Kosunen, 1991). This is in accord with biopsy-verified
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results of the prevalence of gastritis in Finland and
Estonia, showing an overall gastritis prevalence 30% at
the age of 30, and over 70% at the age of 60 (Siurala et
al., 1968; Kekki et al., 1977). Approximately half of all
adults are colonised by the age of 60 in developed
countries (Taylor and Blaser, 1991). In France, less than
1% of children were found to be infected before the age of
6, while 5% of children aged 6 to 12 years and 15% of
children aged 15 to 18 years were infected (Megraud et al,
1989). Similarly, in England, Jones et al. (1986) found
that 10% of healthy blood donors under 20 years of age were
seropositive for H.pylori, compared with 50% of persons
over 50 years of age.
In developing countries, H.pylori infection begins
earlier and also shows an age-dependent increase, reaching
even higher rates of infection than in developed countries
(Megraud et al., 1989; Perez-Perez et al., 1990). In
Vietnam, 40% of 43 teenagers were found to be infected
(Megraud et al., 1989). In the Ivory Coast, 55% of 116
children between the ages of 3 and 6 were infected
(Megraud et al., 1989). In rural Thailand, 18% of children
aged 5 to 9 years were infected, a rate that reached 55% by
age 30 years and 75% by age 50 years (Perez-Perez et al.,
1990). In contrast, in an urban Thai orphanage, 74% (27) of
children aged 1 to 4 years were seropositive. 60% of
persons from the People's Republic of China who were aged
20 to 39 years were infected (Lambert et al., 1990). In
Thailand and Vietnam there appears to be a slight decrease
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in seroprevalence in the elderly.
Prevalence rates plateau or decline after the age of 60
years in most populations. In a number of studies in both
developed and developing countries the age-specific
prevalence of infection was virtually identical in men and
women (Megraud et al., 1989; Graham et al., 1991).
The acquisition of H.pylori continues with increasing
age and appears to last for years, decades (Coghlan et
al., 1987) or for life (Tytgat et al., 1990). Among adults
in developed countries, the annual incidence of infection
appears to be about 1 to 2% (Tytgat et al., 1991; Rautelin
and Kosunen, 1991).
Several investigators have shown considerable
differences in the prevalence of H.pylori infection in
different ethnic groups (Graham et al., 1991). The
Australian aboriginal population showed a low prevalence of
H.pylori antibodies (Dwyer et al., 1988), whereas in the
United States evidence of H.pylori infection was more often
seen in persons originating from China and India than in
those from Mexico or America (Graham et al., 1988). Bertram
et al. (1991) also reported that the characteristics of
gastritis associated with H.pylori infection are influenced
by geographical factors.
H.pylori infection has an inverse relationship with
socio-economic status in both developed and developing
countries (Al-Moagel et al., 1990; Taylor and Blaser, 1991;
Fiedorek et al., 1991; Sitas et al., 1991; Graham et al.,
1991).
The natural reservoirs and mode of transmission of
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H.pylori are still a matter of speculation. The
gastrointestinal tract of human and other primates are the
only known source or reservoirs of H.pylori. Helicobacter
mustelae can be isolated from the gastric mucosa of
ferrets (Fox et al., 1988; Tompkins et al., 1988); however,
neither Helicobacter mustelae nor the organisms found in
swine (Jones et al., 1987) or primates (Bronsdon and
Schoenknecht, 1988; Baskerville and Newell, 1988) can
explain the world-wide distribution of H.pylori infection.
It is tempting to incriminate water as a source of
H.pylori (Klein et al., 1991; West et al., 1992) but no
convincing evidence for this has yet been published. The
motile spiral form of H.pylori has been shown to survive
for at least a week in river water (Shahamat et al., 1989);
while the coccoid form can survive in river water for at
least a year or more (Tytgat et al., 1990).
Attempts to isolate H.pylori from food and soil have
been unsuccessful (Cover and Blaser, 1992). It is likely
that infection is transmitted from person to person.
Evidence supporting this includes the higher prevalence of
antibodies to H.pylori in institutionalised mentally
retarded persons (Berkowicz and Lee, 1987), military
barracks (Vaira et al., 1991), family contacts of H.pylori
positive patients (Reiff et al., 1989; Drumm et al., 1990),
household contacts of H.pylori positive subjects (Bologna
et al., 1992), orphanage children (Reiff et al., 1989),
and endoscopy staff (Mitchell et al., 1989; Reiff et al.,
1989) . Not all these trends are clear cut, however. Jones
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et al. (1987), found no higher percentage of seropositivity
in blood relatives of seropositive patients living in the
same household. Collins et al. (1992) using a urea breath
test reported that the prevalence of H.pylori infection is
higher among younger age groups and spouses. This report
also suggested person to person spread of this organism.
Sexual transmission has also not yet been proved (Taylor
and Blaser, 1991).
Recently, Thomas et al. (1992) have reported for the
first time the isolation of H.pylori from stool in 10 of
24 Gambian subjects. They used very careful handling of
materials in a suitable gas mixture before culture. Thus
there is now a real possibility that faecal-oral
transmission of H. pylori is the main means of
transmission. If so, it would certainly explain much of the
organism's pattern of distribution.
Mouth to mouth transmission still remains a possibility.
Although H.pylori has not been isolated from saliva
(Rosenthal et al., 1988; Krajden et al., 1989), Gobert et
al. (1990), using the polymerase chain reaction, detected
the H.pylori genome in saliva from six of 10 infected
persons. An identical strain of H.pylori was found in the
stomach and dental plaque of a single individual (Krajden
et al., 1989). Maternal premastication of food has been
shown to be a risk factor for acquisition of H.pylori
infection in young children (Albenque et al., 1990).
Occasionally H.pylori has been transmitted from person to
person through improperly cleaned endoscopes (Langenberg et
al., 1990).
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The oral cavity and especially dental plaque might be
the natural source or reservoir of H.pylori for infection
or re-infection of stomach and consequently relapse of DU.
Part of this thesis describes attempts to isolate
H.pylori from the mouth and examines the relationship of
oral H.pylori strains to those isolated from the antrum of
the same patients.
I.2.2 PATHOGENIC MECHANISMS OF H.pylori
H.pylori resides very closely apposed to and indents
the apical membrane of mucus cells (Lee et al., 1985;
Steer, 1985; Buck et al., 1986; Chen et al., 1986; Goodwin
et al., 1986, Bode et al., 1988) or the luminal surface of
mucus secreting cells within gastric pits. It does not
invade the tissues (Jones et al., 1984; Rollason et al.,
1984 ; Tricottet et al., 1986; Blaser, 1987). A few lie
within the mucus layer or more usually between the mucus
layer and the underlying gastric epithelium (Hazell et al.,
1986) . H.pylori clusters above the tight junction between
adjacent cells and can also be found between cells (Fung et
al., 1979; Chen et al., 1986; Hazell et al., 1986; Goodwin
et al., 1986; Bode et al., 1988). The cell wall of H.pylori
contains a lectin (Evans et al., 1988) which selectively
binds the organism to the mucus cell layer and the
epithelial cell membrane. Lectins allow H.pylori to
attach tightly to gastric epithelial cells (Slomiany et
al., 1989). After attaching to the epithelial cells,
H.pylori leads to polymerisation of actin below the
40
epithelial cell membrane and generation of a cell
structure called "attachment pedestals" by which it is
attached to the plasma membrane (Goodwin et al., 1986;
Smoot et al., 1989; Rosenberg et al., 1991).
H.pylori is protected from the harmful effect of acid
by its production of urease which metabolises urea to
ammonia (Hazell et al., 1986; Marshall et al., 1990; Mobley
et al., 1991). Ammonia may in turn damage the gastric
mucosa. Other toxic factors produced by H.pylori (Cover
et al., 1989) are: ureolysin, a mucin-degrading enzyme;
proteases and endopeptidases which damage mucosal
glycoproteins (Slomiany et al., 1987; Blaser, 1990);
catalase, which inhibits the bactericidal effect of
neutrophils (Babiour 1978; Tytgat et al., 1991; Marshall,
1991; Newell, 1991); phosphatase; cytotoxin which is a 13
kilodalton polypeptide producing cellular toxicity (Leunk
et al., 1988; Figura et al., 1989 ; Leunk et al., 1990;
Leunk, 1991; Blaser, 1992).
H.pylori flagella allow it to penetrate the mucus
gel (Hazell et al., 1986). In addition, H.pylori exerts a
mucolytic effect (Siderobotham and Baron, 1990; Sarosiek et
al., 1991) and decreases the hydrophobicity of the mucus
layer (Mertz and Walsh, 1991). The cytotoxic effect of
ammonia (Blaser, 1990; Cover et al., 1991; Mobley et al.,
1991; Triebling et al., 1991) follows damage to the
surrounding cells at the tight junction between epithelial
cells. As a consequence hydrogen ions diffuse back across
the mucus layer (Hazell et al., 1986). Ammonia resulting
from H.pylori urease activity also increases antral pH and
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stimulates gastrin release and causes acid secretion (Morris
et al., 1987; Levi et al., 1989; Graham, 1991, Levi, 1991,
Triebling et al., 1991; Beardshall, 1992) potentially
leading to hyperacidity (Levi, 1989). The finding of
hypergastrinaemia due to increased pH in the antrum has not
been confirmed by other observers (Chittajallu et al.,
1991; Nujumi et al., 1991; Chittajallu et al., 1992).
Somatostatin, released from gastric D cells, has an
inhibitory effect on gastric acid and gastrin secretion.
Following infection of the stomach by H.pylori, gastric
somatostatin secretion is diminished; conseguently, the
inhibitory function of somatostatin is insufficient to
reduce gastric acid and gastrin secretion and this
predisposes to DU. (Moss et al., 1992; Kaneko et al.,
1992) .
After the initial infection of the stomach with
H.pylori, gastric acid secretion becomes lower than normal
for a short period (Graham et al., 1989; Rademaker and
Hunt, 1991). Hyperacidity leads to gastric metaplasia in
the duodenal mucosa (Wyatt et al., 1987 and 1990; Wyatt,
1989; Dixon, 1991). In addition type B gastritis induced by
H.pylori releases neurotransmitters which increase the
motility of the upper gut, decrease duodenal buffering
capacity and consequently lead to duodenal mucosal injury
(fig. 1.6) and gastric metaplasia (Wyatt et al., 1990).
Although H.pylori is always associated with abnormal
gastric mucosa, the organisms are unevenly distributed in
the stomach (Goodwin et al., 1985). H.pylori is present in
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H. pylori gastritis
Fig. 1.6 Pathogenic mechanisms of H.pylori leading to duodenal ulcer
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the duodenum only in association with gastric metaplasia
and has never yet been found on normal duodenal mucosa
(Rollason et al., 1984; Rathbone et al. , 1986; Shabib,
1992). Conversely in the antrum the organisms are never
found in areas of intestinal metaplasia but overlie the
inflamed gastric mucosa surrounding the metaplastic tissue.
This could reflect the presence of specific receptors for
H.pylori in gastric cells that are absent from the cells of
the small intestine, although the existence of these
receptors has yet to be confirmed (Tytgat, 1989). If there
is gastric metaplasia in the duodenum, H.pylori from
antral type B gastritis colonises this area (Price, 1988);
and, this is ultimately followed by duodenitis and DU
(Levi et al., 1989; Dixon, 1991; Madsen et al., 1991).
Different strains of H.pylori might have different
pathogenic effects. Organisms which provoke a gastric IgA
antibody response are more likely to be ulcerogenic
(Crabtree et al., 1991; Holcombe, 1992).
These pathogenic processes also induce degranulation of
mast cells (McGovern et al., 1991) and activate the
classic complement pathway (Blaser, 1990) .
The mechanisms by which H.pylori antigens elicit an
inflammatory response has been extensively studied (Wyatt
and Rathbone, 1988). A soluble bacterial component attracts
phagocytic cells (neutrophils and macrophages) into the
gastric glands and lamina propria leading to gastritis
(Craig et al., 1989; Craig et al., 1992). Inflammatory
reactions induced by H.pylori also contribute to tissue
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damage and a breakdown of normal defence mechanisms
(Rathbone et al., 1988; Blaser and Brown, 1989). The
inflammatory responses might be due to H.pylori urease
absorption at the mucosal surface eliciting chemotactic
activity for leukocytes (Heatley, 1991; Wallace, 1991;
Mooney et al., 1991; Mai et al., 1992).
In the affected area there are many plasma cells which
produce specific IgG and IgA. Complement activation occurs
in the presence of IgG and H.pylori antigens. Complement
activation also occurs via the alternate pathway and
enhances neutrophil chemotactic activity (Das et al.,
1986) . H.pylori infection also leads to the accumulation of
suppressor T lymphocytes.
Histologically active chronic gastritis is
characterised by spotty epithelial necrosis and
microerosions, depletion of gastric mucus,
polymorphonuclear leucocytosis permeating the epithelial
layer, glandular abcess, and acute and chronic inflammation
in the lamina propria (Lee and Hazell, 1988 ) .
Ultrastructurally the surface epithelial cells show
oedema, mucosal bulging, degranulation or depletion of
mucus granules. Surface microvilli are sparse or absent
(Goodwin et al., 1986; Goodwin, 1988).
The evidence linking H.pylori to peptic ulceration
(Malfertheiner, 1988; Tytgat, 1989; Megraud and
Lamouliatte, 1992) can be summarised as follows. There is
a very strong association between H.pylori infection, type
B gastritis and peptic ulcer disease. This cause and
effect relationship has been confirmed in volunteer
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studies. Type B gastritis, the histological change
associated with H.pylori infection, is unique to infection
with this organism. There is evidence of person to person
spread of gastritis and DU and for clustering in families.
There are high ulcer relapse rates after healing with H2
receptor antagonists if H.pylori persists in the stomach
and H2 receptor antagonists by themselves do not relieve
gastritis. Bismuth subcitrate and antibiotic treatment
heals DU and the ulcer recurrence is less likely after
healing with antibiotics (amoxycillin / tetracycline,
metronidazole) than after healing with H2 receptor
antagonist drugs. Ulcer healing after treatment with
antibacterials effective against H.pylori is associated not
only with disappearance of the organism but also with the
restoration of normal gastric mucosa. The majority (85-
100%) of H.pylori infected cases are associated with DU.
H.pylori is associated with early DU recurrence. Ammonia,
produced by the organisms' specific urease enzyme acting on
urea, neutralises acid and helps to create an ideal
environment for the organism in the gastric mucosa.
H.pylori adheres to specific target mucosal surface cells
in the antrum and metaplastic antral type cells in the
duodenum. H.pylori penetrates into the intracellular
spaces and, in some cases, invades the epithelial cells
themselves. There is induction of local and systemic
immunoresponses to H.pylori. H.pylori is absent in
patients with type A gastritis and in histologically
normal mucosa.
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Evidence against the role of H. Pylori in the
pathogenesis of duodenal ulcers is less convincing; however
not all H.pylori infected persons develop DU. Although
relapse is associated with the continued presence of
H.pylori, H2 antagonists with no antibacterial activity
effectively heal ulcers. DU might be present when H.pylori
is not (although this is rare).
I.3 BILE ACIDS AND H.pylori
Duodenogastric reflux which has been postulated to
disrupt the mucosal defence barrier of the stomach leading
to bile specific gastritis and ulcer. H.pylori are not
found in presence of biliary gastritis (O'Connor et al.,
1986b). In contrast others have reported that H.pylori can
colonise the gastric remnant following gastric surgery and
cause gastritis (Loffeld et al., 1988).
1.4 H. pylori AND GASTRIC CARCINOMA
In addition to the clear association between the
presence of H.pylori and type B gastritis, (McKinlay et
al., 1990; Peterson, 1991) a link has been proposed between
the organism and gastric cancer (fig. 1.7). It has been
postulated that type B gastritis due to H.pylori leads to
intestinal metaplasia, atrophic gastritis, achlorhydria and
finally gastric cancer. While this idea is attractive,
this sequence is largely unproven. Dooley (1991) reported




















Fig. 1.7 Association of Helicobacter pylori with various pathologic lesions of the
upper gastrointestinal tract.
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gastritis induced by this organism could act as the fertile
soil upon which other environmental variables come to bear.
In favour of the proposed link between H.pylori and gastric
cancer, Loffeld et al. (1990) reported the frequent
presence of H.pylori in biopsies taken from mucosa not
involved by gastric cancer. Forman et al. (1990; 1991)
found that antibodies to the organism are present in the
majority of gastric cancer patients. It has also been
suggested that there is an increased risk of gastric cancer
in H.pylori positive patients in America (Parsonnet et al.,
1991) and a similar conclusion has been reached about the
Japanese population living in Hawaii (Nomura et al., 1991).
In contrast, two studies failed to show a relationship
between the presence of H.pylori antibody and the presence
of gastric cancer in indigenous Japanese (Fukuda et al.,
1992; Igarashi et al., 1992), and this was also the
conclusion drawn from multi-centre studies in Italy (Miglio
et al., 1992; Farinati et al., 1992). In another study,
H.pylori infection was rather uncommon in the presence of
either atrophic gastritis or intestinal metaplasia, both of
which are accepted as pre-cancerous lesions (Testoni et
al., 1992) .
Part of this thesis describes attempts made to clarify
the relationship between the presence of H.pylori and
gastric cancer by examining histologically stomachs
resected from patients with benign or malignant gastric
diseases.
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1.5 ANTIBIOTIC TREATMENT OF H.pylori INFECTION
The discovery of H.pylori and its relationship to type
B gastritis has not only brought new insights to the
pathogenesis of gastritis and peptic ulcer disease but also
has necessitated critical review of the treatment of these
conditions. The efficacy of antiulcer treatment is measured
by its capacity to provide symptomatic relief, to induce
ulcer healing, to prevent ulcer relapse, and to avoid the
complications of peptic ulcer disease. Data from many
sources confirm that the prevalence of H.pylori in patients
with DU is between 85 and 100%, compared with approximately
40% in an unselected Western population (Shallcross et al.,
1989; Axon, 1991). Relapse of DU is 20 times more likely
if H.pylori persists in the gastroduodenal mucosa or
reinfects it than if it is absent (Axon, 1991). To treat DU
disease and to prevent its relapse, attempts must be made
to eradicate H.pylori from the stomach and at the same time
to prevent it from becoming reinfected. As an extension of
this idea, if there is a relationship between H.pylori
infection and gastric cancer, eradication of the organisms
from the stomach might prevent gastric cancer.
During the last few years different antimicrobials have
been tried alone or in combination in different doses and
for different durations to try to eradicate H.pylori from
the gastroduodenal mucosa.
Triple therapy with bismuth, amoxycillin and
metronidazole was considerably more effective than bismuth
alone in achieving H.pylori eradication at one month and
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resulted in a significantly reduced rate of DU relapse over
the next 12 months (Rauws and Tytgat, 1990). Triple
therapy with bismuth, tetracycline, and metronidazole
achieved more rapid DU healing than ranitidine alone
(Graham and Borsch, 1990). Bismuth with metronidazole and
either amoxycillin or tetracycline eradicate H.pylori in
80-90% of individuals (Axon, 1991) . Recent trials which
have been reviewed by Axon (1991) studied patients whose
ulcers have been healed by a variety of medicaments and who
have then been followed for both H.pylori status and DU
recurrence. Six studies assessed H.pylori status one month
after the end of treatment. When H.pylori was still
present, 96 of 114 patients (84%) subsequently relapsed,
compared with only 20 of 179 patients (11%) when it had
been eradicated. Ten studies have assessed H.pylori status
at the time of relapse. The combined data from the eight
studies which followed patients for longer than nine
months show that ulcer recurred in only six of 217 patients
(3%) in whom H.pylori was absent, compared with 116 of 155
patients (74%) in whom it was identified. The relapse rate
of 11% following eradication is considerably less than
either the 82% found after treatment with H2 receptor
antagonists or the 53% following treatment with bismuth
(Coghlan et al., 1989). Similar findings were reported by
Marshall et al. (1988). They showed that if H.pylori
persisted in the stomach, 61% of DU healed and 84%
relapsed. When H.pylori was cleared, 92% of ulcers healed
and only 21% relapsed during a 12-month follow-up period.
1.6 DIAGNOSIS OF H.pylori INFECTION
Before starting to treat H.pylori infection, it must be
reliably diagnosed (Rauws et al., 1988). Routine diagnostic
methods include: culture of biopsy material, direct
microscopy, histological examination, urease test of
material from antral biopsy, detection of antibody against
the organism and the 14C-urea or 13C-urea breath test. In
addition the technique of chromosomal DNA fingerprinting
can be applied to confirm the identity of the organism.
1.6.1 CHROMOSOMAL DNA FINGERPRINT
Owen (1989) has reviewed the value of chromosomal DNA
fingerprinting methods for identifying species and strains
of microbial pathogens. DNA-probe technology has enormous
potential in clinical diagnostic microbiology offering
faster and cheaper identification of fastidious pathogens.
DNA fingerprints are highly sensitive to minor genomic
variations in nucleotide sequences for characterising
species and for identifying individual strains of closely
related bacteria when more traditional typing methods are
unsuitable or unavailable.
1.6.2 CHROMOSOMAL DIGEST ANALYSIS
Analysis of genomic DNA by base composition (guanine +
cytosine mol%) estimation and DNA-DNA hybridisation have
provided an invaluable basis for defining closely related
groups of microbial strains. Methods of identifying
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strains include plasmid and whole cell protein
electrophoretic profiles. The most precise and most widely
used is bacterial restriction-endonuclease digest-analysis
(BRENDA). BRENDA is a sensitive means of directly detecting
minor genomic differences between micro- organisms.
Restriction endonucleases specifically cleave DNA into
different lengths, depending on the number and position of
the individual recognition sequences, consisting in most
cases of four or six nucleotides arranged in a specific
order.
DNA polymorphism can result from a change in the size of
restriction fragment. If a change occurs in the sequences
of the genome DNA - even a single nucleotide-base mutation
- this can delete a site or create a new recognition site.
The change results in the generation of a restriction
fragment- length polymorphism (RFLP), new DNA
polymorphisms most often represent neutral mutations and do
not cause any phenotype change.
DNA fragments generated by restriction-enzyme digestion
are separated according to size by electrophoresis in
agarose gels to give a pattern of bands. BRENDA has been
used to distinguish between strains of various bacteria.
The usefulness of such patterns as diagnostic tools is
limited by their complexity because they can comprise 50 or
more bands of various sizes depending on the cutting
frequency of the restriction endonuclease used and the
genome size of the organism. It is difficult to
identify minor, but possibly significant, restriction
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fragment-length polymorphisms (RFLPs) in complex multiband
patterns of closely related strains.
When the separated DNA fragments are transferred by
capillary blotting on to nitrocellulose or nylon membranes
(Southern, 1975), the location on the membrane of a
restriction fragment containing a particular gene or
nucleotide sequence can be determined by hybridisation with
a specific labelled nucleic acid probe. The resultant
hybrid-band pattern provides a unique and reproducible
fingerprint. The DNA-hybridisation reaction consists of the
probe, the target DNA and a reporter molecule on the probe.
The key component in Southern-blot hybridisation is the
probe which is a sequence of single-stranded nucleotides
containing a reporter molecule that can search out and
hybridise to stretches of the target DNA- or RNA-containing
complementary sequences. Nucleic acid probes are used in
Southern-blot hybridisation analyses with the purpose of
highlighting specific DNA restriction-site heterogeneities,
which in turn can be used to detect strain differences both
within and between species. The advantages of DNA
fingerprinting by probe hybridisation are: patterns are
relatively simple (maximum 10 bands) to facilitate
comparisons between strains; applicability to any micro¬
organism; reproducibility; wide range of restriction
enzymes available; commercially available rRNA can be used
as a broad spectrum probe; biotin is an excellent reporter
molecule in probes; high sensitivity to minor genome
variations; and pattern matching can be computerized. The
disadvantages are: loci detected by probe might not be
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representative of a genome; and the method is relatively
time consuming. Among various probes used for this purpose,
ribosomal (r)RNA sequence probes are most widely used. In
bacteria many of the rRNA-cistron sequences appear to have
changed little during evolution and so DNA probes specific
for these sequences can detect a wide range of bacteria
containing similar sequences.
DNA fingerprinting is relatively laborious and not
suitable for routine use in the clinical laboratory and is
mostly used in epidemiological studies. Ribopatterns
provide a precise fingerprint for individual strain
identification and are clearly more discriminatory than the
phenotypic differences between strains of H.pylori.
In the present study, DNA fingerprinting was used to
examine H.pylori isolated from the pyloric antrum and from
tooth plaque of the same individual.
1.6.3 UREASE TEST
H.pylori produces a powerful urea-spliting enzyme and
tests for this urease are widely used to identify H.pylori
infection. A urease test is usually done by putting antral
biopsy material into the well of a commercially prepared
strip which also holds a gel pellet containing urea,
phenol red (a pH indicator), and sodium azide. During
manufacture, the gel is buffered to an acid pH which gives
it a bright yellow colour. The colour of the gel changes to
pink if the pH rises above 6. This colour change should
occur only when urea in the gel is hydrolysed to release
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ammonia, i.e.. urease is present. The time needed for a
clear positive reaction is usually 20 min to 1 hour. The
urease test is widely used to identify H.pylori infection
and is considered valid because of its simplicity,
rapidity, low cost, ease of execution, high sensitivity
and specificity (Marshall et al., 1987; Hazell et al.,
1987; Ameglio et al., 1991). The reported sensitivity and
specificity of the urease test varies from author to
author. The sensitivity has been variously reported as 62%
(Coudron et al., 1989), 90% (Borromeo et al., 1987), 91%
(Hazell et al., 1987; Morris et al., 1986a; Marshall et
al., 1987), and 100% (Conti-Nibali et al., 1990). Vaira et
al. (1988a) stated that 62% of positive cases are detected
compared with other tests. The specificity was 87.5%
(Conti-Nibali et al., 1990) and 100% (Hazell et al., 1987).
At present (late 1992) the urease test costs one pound
sterling. In developing countries such a cost while modest
by Western standards is of considerable importance to less
robust economies. If the cost of this test and the time to
carry it out could be reduced significantly this would be
helpful for developing countries.
Part of this thesis describes the preparation and use
of an "in-house" urea solution which minimises the cost of
the urease test for H.pylori, maintains satisfactory
specificity and provides a result faster than the
commercially available urease test.
The 14C-urea or 13C-urea breath test was not used in





Experiments were conducted on patients recruited from
outpatient clinics, endoscopy list and hospital wards. The
number of patients was dependent upon availability from
these sources. The same patients were studied in chapter 3
and 4. Different groups of patients were studied in
chapters 5,6,8 and 9.
CHAPTER 3
Duodenal ulcer and its relationship to fatty acid in the
diet and in adipose tissue, cigarette smoking and age
This chapter is devoted to the relationship between
linoleic acid and DU formation. Previous work had
established low adipose tissue linoleic acid content in DU
patients, suggesting low dietary linoleic acid intake among
these individuals. Dietary linoleic acid influences gastric
PG output; and, this may, therefore, be of importance in
the aetiology of DU. In this chapter dietary total fat,
linoleic acid intake, and the adipose fatty acid content
were examined in DU and matched non-ulcer dyspepsia control
subjects. The influence of smoking was also examined.
The purpose of these studies was to establish whether
the low adipose linoleic acid fraction was due to dietary
deficiency, abnormal linoleic acid metabolism or smoking.
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CHAPTER 4
Helicobacter pylori and Duodenal Ulcer related to fatty
acid in the diet and in adipose tissue and to history of
cigarette smoking and age
The relationship between adipose percentage linoleic
acid (and other factors studied in chapter 3) and H.pylori
status is examined in this chapter. Because low adipose
linoleic acid content in DU patients could be due to
linoleic acid metabolism by H.pylori, the ability of
H.pylori to hydrogenate linoleic acid using a simple in
vitro culture techniques was assessed. Two possibilities
are that the organism digests dietary linoleic acid or less
plausibly, that H.pylori metabolises the linoleic acid
present within the cell membranes of gastric epithelia
resulting in mobilisation from fat stores. The latter seems
unlikely since linoleic acid levels in the stomach and
duodenal mucosa are normal.
CHAPTER 5
Culture of H. pylori from Antral Biopsy, Dental Plague or
material obtained by tooth picking
The possibility that dental plaque acts as a reservoir
for H.pylori re-infection of the stomach was studied in
this chapter. Plaque and gastric mucosa were examined for
H.pylori by enzymatic, microscopic and DNA ribotyping. In
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five patients homology of H.pylori in plaque and gastric
mucosa was determined using DNA ribotyping.
CHAPTER 6
Presence of H.pylori in the Mouth of Hospital Inpatients
The epidemiolgy of H.pylori infection in dental plaque
was examined in separate populations of hospital inpatients
admitted for reasons other than DU. The influence of
previous antibiotic therapy upon the presence of the
organism in plaque was sought. This appears important
because it is possible that systemic antibiotic therapy may
not disinfect the teeth and re-infection of the stomach
after triple therapy (bismuth subcitrate, amoxycillin and
metronidazole) may be a consequence of this failure.
CHAPTER 7
The Effect of Bile Acids on H.pylori Growth In Vitro
Biliary gastritis and type B gastritis are different
entities, but the role of H.pylori in the pathogenesis of
biliary gastritis is unknown. It is possible that bile
inhibits the growth of H.pylori and if so the influence of
the organism in biliary gastritis will be negligible. To




H.pylori and Gastric Carcinoma
It has been suggested that H.pylori gastritis
predisposes to gastric cancer. The sequence of type B
gastritis, gastric atrophy, intestinal metaplasia and
gastric cancer has been postulated but not proven. To
examine the relationship between H.pylori (at the time of
surgery) and gastric cancer, histological evidence of the
organism was sought in gastrectomy specimens from gastric
cancer and a control group of gastrectomies performed for
peptic ulcer.
CHAPTER 9
The Development of a Cheap and Sensitive Urea Solution
For use in Urease tests
The commercially available Campylobacter pylori like
organism (CLO) test for detecting H.pylori is relatively
expensive. A cheaper version with potential for use in




AND ITS RELATIONSHIP TO
FATTY ACID IN THE DIET
AND IN ADIPOSE TISSUE,
CIGARETTE SMOKING AND AGE
3.1 SUMMARY
To examine the relationship between dietary linoleic
acid, adipose tissue linoleic acid, smoking, age and DU, a
detailed prospective dietary history was obtained from 30
DU patients and 26 matched non-ulcer dyspepsia controls of
similar age. The fatty acid profile in adipose tissue was
measured chromatographically in biopsies taken from each
individual. Dietary fatty acid intake was also guantitated.
Mean total dietary fat intake and linoleic acid intake
were similar in DU and non-ulcer dyspepsia control
subjects. In contrast, mean % adipose tissue linoleic acid
was significantly lower in DU patients than control
subjects (p<0.002) . Mean adipose % linoleic acid was
significantly lower in smokers than non-smokers in both DU




Previous studies showed that DU patients tend to have a
reduced adipose tissue linoleic acid content compared to
age matched control subjects (Grant et al., 1988). This has
potential importance since the same group had also shown
that dietary linoleic acid influenced gastric PG secretion
(Grant et al., 1988). Wood et al. (1987) had previously
suggested that adipose fatty acid contents closely reflects
dietary intake and Grant et al. therefore postulated that
relative dietary linoleic acid deficiency may be
aetiologically important in DU. The association between
smoking and DU is well established (Eastwood, 1988; Hudson
et al., 1990) and smokers have reduced adipose linoleic
acid content (Wood et al., 1987).
In this chapter the relationship between dietary linoleic
acid, adipose linoleic acid, smoking, age and DU is re¬
examined. The hypotheses that low adipose % linoleic acid
is due to 1) reduced dietary intake; 2) smoking; 3) altered
linoleic acid metabolism; 4) age, were examined.
3.3 MATERIALS AND METHODS
3.3.1 SUBJECTS
Thirty subjects comprising 22 males and 8 females,
ranging in age from 30 to 80 years (mean 54 years), all
native Scots and all with endoscopically proven DU, were
randomly selected and studied. All had long histories of
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dyspepsia with signs and symptoms of DU, but none had recent
acute gastrointestinal haemorrhage, a past history of
gastric surgery, gastric malignancy, reflux oesophagitis
nor treatment with drugs such as H2 receptor antagonists,
antibiotics, bismuth subcitrate ("De-Nol"), non-steroidal
anti-inflammatory drugs (NSAIDs), steroids or
anticoagulants at any time during the four weeks before
the study began. Ten were cigarette smokers.
DU was diagnosed at endoscopy if at least one deep ulcer
crater greater than 0.5 cm in diameter within the duodenal
cap was present.
Controls
Subjects with DU were matched with 26 controls of
similar age, sex, and smoking history. All efforts to find
a further four controls failed. The control subjects were
patients who had symptoms suggestive of peptic ulcer but
who at endoscopy did not have an ulcer. Nineteen were
males and 7 females ranging in age from 30 to 80 years
(mean 55 years). Eight were cigarette smokers. The smokers
in both groups were matched for their daily consumption of
cigarettes. Non-smokers were defined as either those who
had never smoked or who had stopped smoking for at least
6 months before the study. The same criteria were used to
exclude subjects from the control group as from the group
with ulcer.
It had been hoped to match the two groups by social
class; however many of the participants were either
retired, unemployed or housewives. The two groups were
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similar in the number of such poorly defined groups , but
these are not categories upon which previous
epidemiological studies were based; therefore social class
was not used in the analysis of the results.
3.3.2 METHODS
3.3.2.1 Study Design
The design of the study was explained to all the
patients at their first visit to the gastrointestinal
clinic. When they understood and agreed with the details of
the study, they signed a consent form. At the same time
they were asked to provide details of their diet, with
special reference to fats, by completing a questionnaire
designed by a senior hospital dietitian. Their smoking
habits and physical complaints were also recorded. Seven
to ten days later, during their second visit, the completed
questionnaires were collected and samples of blood and
biopsies of subcutaneous adipose tissue (see below) were
obtained. The serum from the blood samples was separated
and stored at - 70° C before analysis within three months.
Antral biopsies were not obtained from this group of
patients.
3.3.2.2 Adipose tissue biopsies
These were obtained by a surgical colleague,
Mr.C.Rajgopal FRCS (Edin), as follows. With strict aseptic
care, 2-3 ml of 2% lignocaine were injected subcutaneously
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into the anterior abdominal wall, preferably in the right
iliac fossa. A small, 1 to 1.5 cm incision was made
through the skin and using scissors, a surgical scalpel and
forceps, a small amount (20-30 mg) of fatty tissue was
collected. The incision was closed using "Steristrips" or,
rarely, by a stitch. The fatty tissue was rinsed in 0.9%
(w/v) saline solution, dried on absorbent paper and stored
in an Eppendorf container at -70° C before analysis.
3.3.2.3 Laboratory analysis of adipose tissue
for fatty acids
3.3.2.3a Materials
The following equipment and chemicals were used: 1)
Elvjehem glass potter homogenisers; 2) QF 15 ml tubes
19/26, MF24/2 ("Quickfit" BDH); 3) Saline solution- 0.9%
NaCl (w/v), (Baxter Health Care Ltd); 4) Isopropanol (BDH)
and Heptane (Sigma) as a mixture of 4:1 (v/v); 5) Heptane;
6) KOH, 0.5% aqueous (w/v), (BDH); 7) Washing solution
consisting of Isopropanol/ Heptane /KOH (0.5%), 4:1:3
(v/v/v), from which the upper (heptane) layer had been
aspirated and discarded; 8) Toluene ("Aristar", BDH); 9)
Sodium methoxide, 0.5 M in dry methanol (BDH); 10) Acetic
acid ("Glacial" BDH); 11) Hexane, (HPLC grade, Rathburn
Chemical); 12) Standard fats: tripalmitin, tripalmitolein,
tristearin, triolein and trilinolein (Sigma), dissolved in
isopropanol and heptane as at 4 above; 13) Chloroform




Fat standards containing tripalmitin, tripalmitolein,
tristearin, triolein and trilinolein were analysed at
concentrations of 0.2, 0.4, 0.6, 0.8, 1, 2 and 3 mg per
ml of fatty acid in isopropanol/heptane solution to which
2 mg of an internal standard was added (see below). The
correlation co-efficient for the standard curves was
greater than 0.99.
To analyse patients' samples, a composite fat standard
containing 1 mg palmitic, 0.5 mg palmitoleic, 0.5 mg
stearic, 1 mg oleic and 1 mg linoleic acid per ml was used.
As an internal standard, triheptadecanoin was used at a
concentration equivalent to 2 mg per ml of heptodecanoic
acid.
3.3.2.3b Methods
The adipose tissue was thawed; 10 mg were rinsed in
saline and homogenised in 3ml of isopropanol/heptane
solution in a QF tube. One ml of the internal standard was
added. Two ml of the composite standard was taken into a
QF tube and one ml of the internal standard and two ml of
isopropanol/heptane mixture added. Adipose tissue and
standards were analysed in duplicate. To each tube, 3 ml of
heptane and 3 ml of KOH solution were added. The tubes were
then shaken for 5 min and then left undisturbed for 10 min
at room temperature; the top layer was transferred to a
second QF tube. To this, 8 ml of washing solution was
added. The tube was shaken for 5 min and centrifuged for 5
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min at 1000-1300 rpra. The top heptane phase containing
triglyceride free from free fatty acid (FFA) and
phospholipids was transferred to a third QF tube and
evaporated to dryness on a sand bath using oxygen-free
nitrogen. One ml of toluene and two ml of sodium methoxide
solution were added and transmethylation (of lipids)
carried out at 50°C in a water bath for 10 min. Acetic
acid (0.1 ml), five ml of water and five ml of hexane were
added, mixed for five min and again centrifuged for five
min. The top layer was transferred to a fourth QF tube and
evaporated to dryness on a sand bath using oxygen-free
nitrogen. Chloroform (0.5 ml), was added to redissolve
fatty acid methyl esters (FAME) before injecting the
samples into the gas liguid chromatograph (GLC). The
injection volume was 3 /xL (Wood and Rimersma, 1987) .
Gas-liquid Chromatography
The GLC (Pye chromatograph 104) was fitted with a
2m/4mm column, packed with 10% GP-DEGS on 80/100 mesh
supelcoport (Supelco Co LTD). The FAMEs were separated at
an oven temperature of 150°C using as the carrier gas
oxygen-free nitrogen (OFN) at a flow rate of 40 ml/min and
flame ionisation detection with output to a "Vitaron" chart
recorder (fig. 3.1).
In order to measure the absolute amounts of individual
fatty acids in adipose tissue, internal standard in a
concentration of 2 mg per ml, was added to both external
standard and samples. This was done to correct for any
minor variations in pipetting during the various extraction









Fig. 3.1 Example of chromatography: fatty acid profile from adipose tissue biopsies
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and also to correct for differences in injection volumes on
to the GLC.
The individual fatty acids were quantified by
comparison with a composite standard using ratios with the
internal standard. Internal standard per se was not
measured.
Mathematical calculation of analysed fatty acids
From the chromatograph trace the height of individual
fatty acids and internal standard were measured in
millimetres, and the ratio of individual fatty acid and
internal standard peak height determined. This ratio was
further divided by the ratio of the standard fatty acid
peak heights to the internal standard peak height and then
multiplied by the standard value in milligrams for the
individual fatty acids. Finally the results in milligrams
of fatty acid was divided by the amount of tissue/test
sample (in milligrams) and multiplied by 100 to express the
results as a percentage.
For example, peak height of linoleic acid in sample =
50 mm, peak height of internal standard in sample = 46 mm,
peak height of linoleic acid as a standard = 60 mm, peak
height of internal standard used in standard = 52 mm,
concentration of linoleic acid used as standard = 1 mg per
sample extracted, adipose tissue analysed in sample= 10 mg.
(504-46)4-(604-52) = 1.084-1.15 = 0.93 X 1 = 0.93 4- 10 = 0.093
x 100 = 9.3 % (linoleic acid).
Peak height was measured to the nearest millimetre. On
average 1 millimetre was equivalent to a fatty acid weight
of 0.02 mg per sample, indicating a satisfactory sensitive
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method. For each chromatogram reading , the peak height of
the internal standard was between 40 to 55 mm. Peaks less
than 5 mm were not measured. This means that the lower
limit of sensitivity was 0.1 mg per sample for each fatty
acid.
The coefficient of variation for assay of the
individual fatty acids was between 4% and 6%, indicating a
proper and satisfactory separation of individual fatty
acids.
3.3.2.4 Statistical methods
Quantitative variables were compared between groups by
student's "t" test or Wilcoxon tests depending on
distribution of data. Spearman rank correlation was used to
test for association between quantitative variables.
Multiple linear regression was used to test whether the
various factors predicted to affect adipose tissue linoleic
acid levels when adjusted for one another.
3.3.3 ANALYSIS OF DIETARY CONSTITUENTS
Each subject was asked to keep details of their diet for
seven consecutive days. This involved their recording in a
diary every item of food or drink consumed. The average
daily intake during the seven day period was then
calculated and the relative preponderance of different
dietary constituents was determined using a computer model
based on the tables of the composition of different foods
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published by McCance and Widdowson (Holland et al., 1991).
Particular attention was paid to the daily intake of
saturated and unsaturated fats. (Dietary data were
quantified by a senior dietitian, Alice Michie).
The accuracy of the assessment of dietary intakes is
dependent on each individual's recording and reliability
of their food measurement.
An example of a dietary diary and food frequency
questionnaires and the way in which diet was assessed from
diaries is shown in appendix 1.
3.4 RESULTS
There was no significant difference in the mean daily
total fatty acid intake of DU patients and control
subjects, whether smokers or non-smokers (table 3.1). In
the case of smokers with DU, mean fatty acid intake tended
to be less (67.69 gm) than in controls who also smoked
(87.18 gm).
The mean % of linoleic acid in adipose tissue was
significantly (p<0.002) lower in the ulcer group (7.73% ±
2.3) than in controls (10.04% ± 3.1) and this was
attributable to differences in non-smokers (see below).
The mean % of other fatty acids did not differ
significantly between the two groups (table 3.2).
The intake of linoleic acid as a percentage of
total fatty acids was similar in the subjects with DU and
in controls (9.9% and 9.7% respectively). The mean %
linoleic acid content of adipose tissue fatty acids in
control subjects was similar to the percentage in their
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diets (10% and 9.7% respectively). The mean % of linoleic
acid in the adipose tissue of DU subjects was
significantly lower than that in their diet (p < 0.05;
table 3.3).
The mean % linoleic acid in the diet of smokers and
non-smokers was similar in both DU patients and control
subjects. Among non-smokers, the mean % adipose tissue
linoleic acid was lower (p<0.001) in those with DU (7.85 ±
1.95) than in the controls (11.98 ± 2.41) but was similar
in DU patients whether they smoked or not (table 3.4).
In addition among non-smokers, the mean % of
monounsaturated fatty acids (MUSFA) in adipose tissue was
significantly lower (p<0.05) in the DU group (40.92 ± 4.82)
than in the controls (44.32 ± 5.59).
There was no significant difference in the weight or
height of DU and control subjects in relation to smoking
(table 3.5). The body mass index of DU patients and control
subjects was not statistically significantly different.
The mean % linoleic acid in adipose tissue was
significantly lower (p<0.001) in smokers (7.6% ± 1.8) than
in non-smokers (9.9% ± 2.2). The distribution of linoleic
acid among smokers was similar in both DU and control
subjects (figure 3.2).
Results of statistical analysis
The mean % linoleic acid in adipose tissue was
significantly lower in the DU group than in controls after
adjustment for age (p< 0.002).
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Table 3.1 The mean daily total dietary fatty acids*
intake in smokers and non-smokers with and without
duodenal ulcer.
n Total dietary fatty acid
intake in gm (SD)
Duodenal ulcer 30 68.76 (23.33)
Smokers 10 67 . 69 (23.07)
Non-smokers 20 69 . 79 (22.55)
control 26 75.09 (26.88)
Smokers 8 87 .18 (31.11)
Non-smokers 18 69. 04 (21.84)
*(Saturated fatty acids, monounsaturated fatty acids
polyunsaturated fatty acids).
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Table 3.2 Mean values of adipose tissue fatty acids (as
% of total fatty acids) in duodenal ulcer and control
subjects.
Fatty acids Duodenal ulcer Control
n = 30 n = 26
mean % (SD) mean % (SD)
Palmitic acid (16:0) 18.21(2.43) 18.59(2.39)
Palmitoleic acid(16:l) 4.28(1.36) 5.1(1.26)
Stearic acid (18:0) 4.09(0.8) 4.35(1.03)
Oleic acid (18:1) 37.4(4.49) 39.39(4.47)
Linoleic acid (18:2) 7.73(2.3)* 10.04(3.1)*
* p < 0. 002.
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Table 3.3 Mean linoleic acid content of diet and adipose
tissue (as % of total fatty acids) in subjects with
duodenal ulcer and controls.
(Linoleic acid)
Adipose tissue Dietary
n Mean (SD) Mean (SD)
Duodenal ulcer 30 7.7(2.3)* 9.9(3.1)*
Control 26 10.04 (3.1) 9.68(2.6)
* p < 0.05,
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Table 3.4 Mean linoleic acid (LA) as % of total fatty
acids in the adipose tissue and in the diet of smokers and




























Table 3.5 The mean height and weight of duodenal ulcer



























































































Mean: Smokers 7.6 ±1.81
Non-smokers 9.9 ± 2.2
* p < 0.001
Fig. 3.2 Linoleic acid as percentage of total fatty acid in the adipose tissue of
smokers and non-smokers with and without duodenal ulcer.
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The mean adipose tissue % linoleic acid was
significantly lower (p< 0.012) in smokers both in DU and
control subjects than non-smokers after adjustment for age.
The mean % linoleic acid in adipose tissue of DU
patients was significantly lower than that in their diet
(p< 0.05).
Dietary linoleic acid did not correlate significantly
with age.
Multiple regression analysis showed no significant
interactions between dietary linoleic acid and any of the
other factors (DU or controls, smokers or non-smokers and
age) as predictors of adipose tissue linoleic acid.
3.5 DISCUSSION
The discussion of this chapter is combined with the
discussion of the next chapter.
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CHAPTER 4
Helicobacter pylori AND DUODENAL ULCER
RELATED TO FATTY ACID IN THE
DIET AND IN ADIPOSE TISSUE,




In same group of patients studied in chapter 3,
H.pylori antibody was measured by ELISA. H.pylori was
cultured in the presence of olive oil using an in vitro
assay.
Antibody titres were significantly higher in the
elderly. This was true for both DU patients and control
subjects. There was no correlations between age, antibody
titre, dietary linoleic acid, or % adipose tissue linoleic
acid. H.pylori did not metabolise linoleic acid in vitro.
4.2 INTRODUCTION
This chapter examines whether the factors studied in
chapter 3 have any bearing on antral infection with
H.pylori. The patients studied in chapter 3 were evaluated
using a ELISA test for H.pylori. The object of the study
being to see if a deficiency of linoleic acid in the
adipose tissue, cigarette smoking or age were factors in
the propensity of an individual to become infected with
H.pylori.
A factor in the reduced tissue linoleic acid content
could be a failure of absorption. There is no evidence
which suggests that this is a reasonable hypothesis;
however, unsaturated fatty acids are known to be
metabolised by colonic bacteria. It is therefore possible
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that H.pylori could also metabolise linoleic acid and
hence reduce the linoleic acid available for absorption.
This has been studied using simple culture techniques.
4.3 MATERIALS AMD METHODS
Antibodies to H.pylori were measured in the DU and
control patients as described in chapter 3. The study
design is identical to that described in chapter 3. Antral
biopsies were not obtained from patients described in
chapters 3 and 4.
4.3.1 ENZYME LINKED IMMUNO-SORBENT ASSAY (ELISA)
FOR ANTIBODY TO H.pylori.
4.3.1.1 Principles
This method involved the absorption of H.pylori antigen
onto the plastic surface of a 96-well plate. Excess
antigen was removed by washing and diluted test serum was
incubated with the immobilised antigen. Unbound human
antibodies were removed by washing. Thereafter any bound
human antibodies usually IgG antibodies, were detected by
incubation with anti-human immunoglobulin, conjugated with
the enzyme peroxidase. The enzyme indirectly bound to the
plate was then detected using a chromogenic substrate. The
enzyme reaction was stopped and the colour product in each
well measured using a plate reader. The assay is
quantitative, the optical density of the colour product




Serum antibody was assayed using a commercially
available ELISA kit, "Helico-G", (Porton Cambridge). This
contained: 1) 12 strips each of 8 microwells coated with
H.pylori antigen stored in a sealed pouch containing
desiccant; 2) two calibrator sera already diluted and
ready for use. Calibrator 1 contained 10 and Calibrator 2
200 units per ml of specific anti IgG antibodies to
H.pylori; 3) Peroxidase-conjugated Fab2 fragment (Goat
Anti-human IgG). This was prepared for use by diluting 1
in 20 with wash fluid (0.25 ml of conjugate to 4.75 ml of
wash fluid); 4) 250 ml concentrated wash/diluent fluid (ten
fold concentrated); 5) Substrate chromogen (tetra methyl
benzidine and urea peroxide) stabilised and ready for use;
6) Reaction stopping solution (2 M sulphuric acid).
Additional materials used were: 1) tubes and vials for
sample dilution; 2) accurate and properly maintained
pipettes for delivering volumes of 5, 10, 20, 50, 100, 200,
400 and 1000 /zl; 3) an eight- channel automatic pipette
with disposable tips (Labsystem group Ltd); 4) multichannel
plate photometer with 450 nm filter (Dynatech Laboratories
Ltd); 5) deionised distilled water; 6) incubator or
water bath at 37°c; 7) microtitration plate shaker
(Denley Instruments Ltd).
4.3.1.3 Methods
The kit was warmed to room temperature. Before
analysing a patient's serum, four standards containing
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respectively 5, 20, 50 and 100 units per ml of antibody
were prepared and analysed by dilution from the standard
calibrator sera containing 10 and 200 units per ml
respectively. Washing fluid (500 ml) was prepared by
diluting 50 ml of concentrated fluid with 450 ml of
deionised water. Before assay each patient's serum was
diluted 200 fold by adding 995 fj,l washing fluid to 5 /x 1 of
serum.
Of the first column of wells, the first two were left
vacant and from the third to eighth row 100 /xl of each of
six different concentrations of the prepared standard
antisera were added in order of increasing concentration.
In the second and subsequent columns 100 /xl of each
patient's serum diluted 1/200 were placed in adjacent
wells. The plates were then incubated at 37° C in a moist
atmosphere for 1 hr. Thereafter the wells were washed three
times with diluted wash fluid and 100 jul of peroxidase-
conjugate was added. The plates were again incubated at
37°C in a moist atmosphere for 30 minutes. The wells were
then washed three times with diluted wash fluid and 100
yu, 1 of substrate added. The plates were shaken mechanically
at room temperature for 10 minutes. Thereafter the reaction
was stopped by adding 50 /xl of 2M sulphuric acid to each
well and shaking the plates to ensure mixing. The underside
of the strip wells were wiped and thoroughly cleaned and
the intensity of any reaction (optical density) measured at
450nm in the photometer within 30 minutes of adding
sulphuric acid. A test was considered positive if the
reading was greater than or equal to that obtained with the
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standard containing 10 units per ml. Serum concentrations
were determined from a calibration curve constructed from
the standard included with the kit.
This method is being used in different centres with
satisfactory results (Newell et al., 1988; Wyatt and
Rathbone, 1989). In this study the coefficient of variation
of the method was 8%.
4.3.2 THE EFFECT OF H.pylori
ON POLYUNSATURATED FATTY ACIDS
Experiments were performed to determine whether
linoleic acid was metabolised by H.pylori to
monounsaturated fatty acids. H.pylori was inoculated in
presence of olive oil in Skirrow's medium and from the
medium linoleic acid was measured (from both medium with or
without inoculation of H.pylori).
4.3.2.1 Methods
Highly refined olive oil (Sigma) was homogenised in
Skirrow's medium at concentrations of 0.1% and 0.5%. In
some experiments 1% Tween 80 (polyoxyethylene-sorbitan
mono-oleate, Sigma) was added as emulsifier to Skirrow's
medium containing 0.5% olive oil. Campylobacter broth
(Gibco) with supplements (Prolab Diagnostic) and 10%
defibrinated horse blood was also prepared with the same
concentrations of olive oil. Tween 80 was added as above to
similar preparations of the broth.
The solid media and broths prepared with olive oil were
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inoculated with H.pylori from colonies grown in Skirrow's
medium from endoscopic antral biopsies. They were then
incubated at 37° C in micro-aerophilic conditions (nitrogen
plus 5% carbon dioxide and 5% oxygen) and in 95-100%
humidity for 5 days. Two different controls were used and
examined in parallel and in the same manner as the tests.
The first consisted of 0.1% and 0.5% olive oil (with
and without Tween 80) in Skirrow's medium and broth but
uninoculated with H.pylori. The second control was
Skirrow's medium and broth without added olive oil
inoculated with H.pylori. Quantitative or semiquantitive
assessment of numbers colonies were not done for H.pylori
observed in the culture plates. All test samples and
controls were analysed in duplicate for fatty acids using
the same methods as for adipose tissue analysis.
4.3.3 Statistical methods
Quantitative variables were compared between groups by
student's "t" test or Wilcoxon tests depending on the
distribution of data. Spearman rank correlation was used to
test for association between quantitative variables.
Multiple linear regression was used to test whether the
various factors predicted adipose tissue linoleic acid
levels when adjusted for one another.
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4.4 RESULTS
The mean % linoleic acid in the diet of the antibody
positive and antibody negative groups did not differ
significantly (p>0.2). The mean % linoleic acid in the
adipose tissue of the antibody positive and antibody
negative groups was similar (table 4.1). Antibody for
H.pylori was positive in 27 (90%) of DU patients and in
4(15%) of control subjects. The antibody titres were
highest in older DU patients (fig. 4.1 a and b) . As
anticipated, antibody titres increase with increasing age
in both DU and control subjects.
Results of statistical analysis
Quantitative serum ELISA antibody concentrations did
not correlate significantly with either % adipose tissue or
dietary linoleic acid. There was a positive correlation
with age (p<0.05) and the concentrations were significantly
higher in DU patients than in controls (p< 0.001).
Multiple regression showed no significant interactions
between dietary linoleic acid and any of the other factors
(DU or controls, smokers or non-smokers, age, guantitative
ELISA value) as predictors of adipose tissue linoleic acid
(table 4.2).
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Table 4.1 Mean linoleic acid as % of total fatty acids
in the diet and adipose tissue of duodenal ulcer and
control subjects related to the presence or absence in
their serum of antibodies to H.pylori.
Antibody present Antibody absent
n = 31 n = 25
mean % (SD) mean % (SD)
Diet 10.7%(2.8)* 9.6% (2.7)*
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Table 4.2 Multiple regression coefficients for prediction
of adipose tissue linoleic acid (LA) from dietary LA and
other factors (DU / control, quantitative ELISA levels,
smoking and age).
Factors Coefficient (Standard error)
Dietary LA 0.34 (0.38)
DU/control -1.27 (2.41)
Interaction -0.11 (0.22)
Dietary LA 0.14 (0.17)
ELISA titre -0. 02 (0.03)
Interaction 0. 000 (0.003)
Dietary LA 0. 10 (0.14)
Smoking -0.61 (3.02)
Interaction -0. 11 (0.30)
Dietary LA 0.28 (0.51)
Age 0. 03 (0.11)
Interaction -0.003 (0.010)
No significant interactions demonstrated.
92
The linoleic acid content (as a percent of total fatty
acids of olive oil) of Skirrow's medium containing
homogenised olive oil was the same (3.85%) whether the
culture medium had been inoculated with H.pylori or not and
incubated, i.e.. growth of H.pylori on the medium did not
reduce the linoleic acid content.
4.5 DISCUSSION
Whilst the identification of H.pylori in the antrum of
patients with peptic ulceration introduces an important new
aetiological factor in chronic gastritis and DU, it is
still not clear why H.pylori infects some individuals but
not others. Cigarette smokers and patients with DU have a
reduced adipose tissue linoleic acid content.
Dietary linoleic acid supplementation increases gastric
PGE output and decreases gastric acid secretion. It has
been suggested that the falling incidence and virulence of
DU is related to increased dietary polyunsaturated
essential fatty acid (linoleic acid) intake. The adipose
tissue fatty acid content is said to closely reflect its
dietary intake.
In the studies described in chapters 3 and 4, the DU
patients and control subjects (smokers and non-smokers)
were similar in both weight and height. The mean dietary
intake of linoleic acid as a % of total fatty acid was
identical in the subjects with DU and non-ulcer dyspepsia
(9.9% and 9.7% respectively). The mean % linoleic acid
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content in adipose tissue of the control subjects was
identical to the mean % linoleic acid in their diets (10%
and 9.7% respectively). The mean daily total dietary
intake of fatty acids by patients with DU who were smokers
was less than that of control smokers (67.7gm and 87.2 gm
respectively), but multiple regression showed that the
dietary intake of linoleic acid did not differ
significantly when comparing DU patients with controls,
smokers with non-smokers or subjects with or without
antibody against H.pylori when controlled for age. Kearney
et al. (1989) showed a lower intake of linoleic acid and a
significantly lower intake of dietary fibre in both
dyspeptic and peptic ulcer patients compared with healthy
controls. They suggested that this difference might be due
to rejection or acceptance of particular food items by
dyspeptic and peptic ulcer patients. In contrast, the
results of the studies reported here show that linoleic
acid intake is not low in DU patients thus rejecting the
suggestion of Kearney at al.. The protocol followed in this
study was not designed to assess the dietary fibre in the
diet.
Quantitative ELISA values did not correlate
significantly with either adipose tissue linoleic acid or
dietary linoleic acid. But elderly (p<0.05) and DU patients
had higher antibody levels than controls (p<0.001). These
findings are similar to published epidemiological studies
(Perez-Perez et al., 1988; Kosunen et al., 1989; Sitas et
al.,1991) .
The mean % linoleic acid in the adipose tissue of DU
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patients was significantly lower than in their diet
(p<0.05); however, there was no statistically significant
difference in these levels when comparing DU patients and
controls, smokers and non-smokers or subjects with or
without antibody or antibody titre to H.pylori when
controlled for age. This finding might be due to different
numbers of DU patients and controls. In a large study
Fulton et al. (1988) showed that cigarette smokers had a
significantly lower intake of polyunsaturated fatty acid
(PUSFA) and fibre (but they did not measure the adipose
PUSFA).
The mean % of linoleic acid but not of the other fatty
acids in adipose tissue was significantly lower in the
ulcer group than the controls (p<0.002). This finding
suggests that linoleic acid levels are indeed important in
DU development, either due to primary deficiency in the
diet (although no such deficiency was found in the present
study) or due to secondary defective metabolism during PG
synthesis. This finding is similar to those of Kearney et
al. (1989) and Grant et al. (1990). Riemersma et al.
(1986) found the lowest proportion of linoleic acid in the
adipose tissue of men from north Kerala (India), and
Finland; the highest was in Italy and levels in Scottish
men were intermediate. In a similar way, regional
differences in peptic ulcer prevalence might be related to
the proportion of linoleic acid in adipose tissue. Langman
(1979) stated that in the UK, the prevalence of DU
increases the further north is the population. It might be,
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therefore, that the increased prevalence of peptic ulcer in
the Scottish population is due to their having less
adipose tissue linoleic acid than the English. In this case
dietary intake might not be the sole variable; the
difference might be related also to differences in
cigarette smoking (Wald et al.,1988).
In addition, the mean % of linoleic acid as a % of
total fatty acid in the adipose tissue in relation to age
of the smokers (7.6 ± 1.8) was significantly lower than
that of non-smokers (9.9 ± 2.2) with or without DU (p
<0.012). The distribution of % adipose linoleic acid among
smokers was similar in both DU and control subjects. By
contrast, among non-smokers, the mean % adipose linoleic
acid was lower in ulcer patients (7.85 ± 1.94) than in
controls (11.98±2.41) (p<0.001). Among non-smokers, the
mean % of monounsaturated fatty acids in adipose tissue was
lower in the DU group (40.92±4.82) than in controls
(44.32±5.59) (p<0.05).
The findings in chapter 3 raise certain possibilities
which might account for the lower % of linoleic acid in the
adipose tissue of smokers and DU patients. The first (but
unlikely) possibility is that smokers are less able to
provide a reliable dietary history than non-smokers.
Secondly, H.pylori which is present in the stomachs of DU
patients might metabolise or hydrogenate linoleic acid to
other saturated fatty acids; thus, the linoleic acid is
utilised by the stomach with a consequent lower % of
linoleic acid in adipose tissue. Watson (1965) showed
that PUSFA are hydrogenated by bacterial activity in the
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colon to saturated fatty acids products. The % of
linoleic acid in the diet and in the adipose tissue of
individuals with or without antibody to H.pylori or
antibody levels, age, smokers or non-smokers, DU or
controls did not differ statistically, nor in addition,
did the experiments in which H.pylori was incubated with
olive oil show breakdown of linoleic acid in this
commonly ingested form. There is no evidence from these
experiments that H.pylori is responsible for the lower %
of linoleic acid in adipose tissue in DU patients. At the
present moment it is not reasonable to believe that
H.pylori is capable of metabolising sufficient linoleic
acid to affect levels in the fat stores.
The data are confounded and might simply reflect the
differences in social class. If social class could be
measured accurately the effect of diet and smoking might
have been clearer.
The remaining possibility is that there might be
abnormal tissue metabolism of linoleic acid in DU patients
who smoke.
Robert (1979) and Miller (1983) showed that PGs
particularly PG2, and PGI2 protect the gastric mucosa. Lam
et al. ( 1986) showed that PGE-l overcomes the adverse
effects of smoking in chronic DU healing. On the other
hand, both PGF2 alpha, a cyclo-oxygenase product with
vascular effect on the submucosal microcirculation (Whittle
et al., 1985) and thromboxane A2 (Tx A2) a potent platelet
aggregator and vasoconstrictor formed by thromboxane
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synthetase (Whittle et al., 1981; Bennet, 1983; Whittle et
al., 1985) might be responsible for gastric injury.
McCready et al., (1985) showed that cigarette smoking
decreases PGE levels and causes peptic ulceration. Fedi et
al. (1990) showed that cigarette smoking decreased PGE2
and increased PGF2 alpha, TxB2 and consequently predispose
to peptic ulceration.
This study has shown that there is a lower adipose
tissue content of linoleic acid in smokers regardless of
whether or not they have DU. NOn-smoking patients with DU
had a reduced adipose tissue linoleic acid content compared
to non-ulcer patients.
Comparison between dietary intake of linoleic acid and
adipose tissue concentration suggest that there is in
smokers some factor which influences the metabolism of
linoleic acid. Zijlstra et al. (1992) showed that smokers
had a significantly higher concentration of eicosanoids in
bronchoalveolar lavage than non-smokers. It is not
unreasonable to suppose that the major influence of
smoking on linoleic acid metabolism is through modulation
of cyclo-oxygenase and lipoxygenase derivatives.
The major quantitative differences in the eicosanoids
are TxB2, PGF2 alpha (cyclo-oxygenase derivatives), 12-
hydroxy-eicosa-tetraenoic acid (HETE) and 15-HETE (both are
lipoxygenase products). It is the products of the cyclo-
oxygenase pathway of arachidonic acid metabolism which are
important in the gastric mucosa. In a similar way, in the
gastric mucosa there might be more PGF2 alpha and TxB2 due
to smoking, with consequent damage to the gastroduodenal
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mucosa and subsequent peptic ulceration.
PGs can protect the gastric mucosa through many
mechanisms (Robert, 1981 and 1984; Miller, 1983; Hollander
and Tarnawski, 1986; Rask-Madsen and Lauritsen, 1987;
Hawkey, 1989; Tovey et al., 1989; Northfield and Goggin,
1991), these include: the maintenance of an intact mucosal
barrier; increasing gastroduodenal bicarbonate secretion
(Feldman, 1983; Isenberg et al., 1986); decreased acid
secretion when given orally or parentally ( Horton et al.,
1968; Classen et al., 1971; Befrits and Johansson, 1985).
This may come about by PGs blocking histamine induced
formation of cyclic AMP (Puurunen, 1983). Some PGs protect
gastric mucosa against injurious agents such as alcohol
(Konturek, 1985), possibly by acting not at the cell
surface but on the microcirculation of the gastric mucosa
or more centrally (Guth et al., 1984).
If gastric mucosal integrity is diminished by smoking
and reduced linoleic acid concentration in the body
tissues, this does not appear to be mediated through an
increased propensity for H.pylori infection of the antrum.
The mechanism may well be through the cytoprotective
elements of the gastric mucosa. There could be a loss of
linoleic acid from the body through the bronchial
secretions or there may be alteration in eicosanoid
metabolism.
DU is associated with changes in linoleic acid
metabolism, probably a decrease in cyclo-oxygenase




FROM GASTRIC ANTRAL BIOPSY,
DENTAL PLAQUE OR MATERIAL
OBTAINED BY TOOTH PICKING
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5.1 SUMMARY
In order to identify the reservoir of H.pylori
infection, tooth plaque cultures were performed in 60
dentulous DU patients, from the dental plates of 3
edentulous DU patients and in 30 age matched non-ulcer
dyspepsia control subjects. Gastric antral biopsies were
subjected to the urease test, histology and culture.
Nucleic acid analysis of H.pylori was done on five pairs of
strains isolated by culture from DU patients.
Fifty nine (94%) DU patients had H.pylori associated
gastritis and H.pylori was demonstrated by histology in
53(84%). H.pylori was cultured in Skirrow's medium from
tooth plaque in 12 patients (19%) and in 56(89%) from
antral biopsies. In DU patients the urease test was
positive in 57% of tooth plaques and 79% of antral
biopsies. H.pylori isolated from tooth plaques and antral
biopsies had an identical nucleic acid structure. Seven
control subjects had H.pylori gatritis, H.pylori was
demonstrated histologically in four, and two of these had a
positive culture from tooth plaque. H.pylori was not
cultured from the dental plates of edentulous individuals
nor was it isolated from saliva or the tooth plaque of
individuals who did not exhibit gastritis.
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5.2 INTRODUCTION
When H.pylori is eradicated from the gastric antrum
using triple therapy there is a more prolonged remission of
DU than if the ulcer is healed by ranitidine. Relapse is
associated with colonisation of the gastric antrum by
H.pylori. The source of the H.pylori could be an external
one, but the regularity of the re-infection suggests a
nidus of infection within the host. The mouth, possibly
dental plaque or saliva were considered to be prime
possibilities. Saliva and dental plaque were cultured and
the H.pylori identified by enzymatic, microscopic, and
ribotyping methods.
5.3 MATERIALS AND METHODS
5.3.1 Subjects
Sixty three subjects, 48 males and 15 females, ranging
in age from 20 to 83 years (mean 50 years) with
endoscopically proven DU (at least one deep ulcer crater
0.5cm in diameter within the duodenal bulb) were studied.
Three were edentulous. All had a long history of dyspepsia
with signs and symptoms of DU but none had recent acute
gastrointestinal haemorrhage, past history of gastric
surgery, malignancy, reflux oesophagitis nor treatment
with drugs such as H2 receptor antagonists, antibiotics,
bismuth subcitrate ("De-No1"), non-steroidal anti-
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inflammatory drugs (NSAIDs), steroids or anticoagulants at
any time during the previous four weeks before the study.
Thirty control subjects of similar age and sex
comprised a control group. Initially the ulcer and control
groups each consisted of 30 subjects, but after initial
success in culturing H.pylori from the dental plaque of DU
patients, this group was extended to 63.
The control patients were those who had symptoms
suggestive of peptic ulcer but in whom an ulcer was not
seen at endoscopy. They comprised 18 males and 12 females,
aged 20 to 81 years (mean 52 years). The same criteria
were used to exclude patients from the control group as
from the group with ulcers. All of the control patients
had at least some of their own teeth.
Antibody against H.pylori was not measured in these
patients. Smoking and social class were not recorded.
The patients were endoscoped in the normal manner. A
mouth guard was placed in the mouth between the teeth prior
to inserting the endoscope. The endoscope was directed
straight into the pharynx to protect the instrument. The
mouth guard is oval, measuring 3x4 cms in size and has a
cusp 5 cms by 4 cms at the front which sits across the
teeth. The important function of the guard to protect the
endoscope from the teeth. By the same token the endoscope
will be quite remote from contamination by dental plaque.
Contamination of the teeth with H.pylori during endoscopy




At endoscopy, macroscopic findings were documented and
three antral biopsies were taken. One was examined
histologically after being stained with haematoxylin and
eosin to determine if type B gastritis was present and
to detect H. pylori. The second was used in a
Campylobacter-like organism (CLO) test for urease. The
sensitivity of the CLO test using an unspecified bacterial
load in antral biopsies is 95% at three hours after
incubation (Morris et al., 1986a; Marshall et al., 1987).
The third biopsy was examined for live H.pylori by
transporting it immediately in 0.5-1 ml of 0.9% saline
solution in a sterile "Universal" container to the
laboratory where within thirty minutes to one hour it was
cultured on Skirrow's medium (Skirrow, 1977). This
contained: Columbia agar base (Gibco Life Technology Ltd)
containing special peptone, 23 gm/L; starch, 1 gm/L; NaCl,
5 gm/L; agar, 10 gm/L. These ingredients were dissolved in
one litre of distilled water and sterilised by
autoclaving at 121° C for 15 minutes. The pH was adjusted
to 7.3. Defibrinated 10% horse blood (Scottish
Biotechnology Instrumentation) 100 ml/L and selective
(Skirrow's) supplements (Prolab Diagnostic) consisting of
vancomycin 10 mg/L, polymixin B 2500 IU/L and trimethoprim
lactate 5 mg/L were added to the cooled but molten base
medium.
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Inoculated plates were incubated for 4-6 days at 37°C
in 95-100% humidity and an atmosphere containing nitrogen,
oxygen and carbon dioxide in ratios of 90:5:5. Colonies
resembling H.pylori, 1 mm in diameter, shiny, convex,
rounded and weakly haemolytic were further examined by
standard tests (Cowan, 1974) for urease, catalase and
oxidase activity and after staining by Gram's method for
typical S - shaped, curved or spiral Gram-negative
bacilli.
Attempts were also made to culture H.pylori from saliva
and tooth pickings. In the endoscopy recovery room
patients were asked to spit saliva into a sterile
"Universal" container. A minimum of 4-5 ml was collected.
This was centrifuged for 15 minutes at 1000 rpm using a
Centaur 1 (M.S.E) centrifuge and the deposit was spread on
Skirrow's medium.
Tooth pickings (plague) were collected after
endoscopy. In the recovery room patients were asked to
scrape between their teeth with a plastic tooth pick
("Pick plak", HWC Supplies). The material produced was
transported to the laboratory in a sterile "Universal"
container and was spread within 15-30 minutes on Skirrow's
medium as described above. From these plates which always
produced mixed bacterial and fungal growth, suspect
colonies of H.pylori were subcultured 2-4 times on
Skirrow's medium until a pure culture was obtained. The
colonies were identified and confirmed as H.pylori by their
morphology, enzyme reactions and nucleic acid analysis.
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Identification and typing of strain by nucleic acid
analysis
This was done by Dr. R.J. Owen, London. Ribotyping was
carried out on five pairs of strains of H.pylori, each pair
consisting of strains cultured from the antral biopsy and
tooth plaque of one individual with DU and on an eleventh
mouth strain from a patient whose antral strain did not
survive after repeated subculture. Confirmation of their
identity as H.pylori was sought by Southern blotting of
HindIII digest probed with a cloned random DNA sequence
(HP7) specific for H.pylori (Owen, 1989; Owen et al.,
1992a). The relatedness (homology) of paired strains from
the mouth and antrum of single patients was examined by i)
Southern blotting of tfaelll digest probed with a 16+23S
and a 16S rRNA gene probe (Owen et al., 1992b); ii) Hindlll
digest probed and in the same way iii) by Southern blots
of Haelll digest probed with a specific 16S rRNA gene probe
obtained by the polymerase chain reaction.
DNA isolation, restriction digestion, and ribosomal RNA
gene probe hybridisation
Chromosomal DNA was isolated and purified using the
guanidium thiocyanate reagent method (Owen, 1989; Owen et
al. , 1992a and 1992b) . All DNA samples (5 /xg) were
digested for four hours at 37°C with Haelll and Hindlll (2-
3 U/ /ug of DNA) . The digested DNA was electrophoresed at 25
V for 16 hours using a horizontal 0.7% (w/v) agarose gel in
a buffer containing 89 mM Tris hydrochloride, 89 mM boric
acid, and 2 mM disodium ethylenediaminetetra-acetic acid
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(EDTA) (pH 8.3). After electrophoresis, the DNA fragments
were transferred to Hybond-N nylon membranes by vacuum
transfer blotting. The membranes were then hybridised by
standard procedure for 18 hours at 42°C with a biotinylated
cDNA probe prepared from a 16S and 23S rRNA mixture of
H.pylori NCTC 11638 using Moloney mouse leukaemia virus
reverse transcriptase. Biotinylation was achieved by the
incorporation of biotin-16-dUTP. The membranes were washed
after hybridisation and the hybridised probe detected
colorimetrically using a non radioactive detection kit-
BlueGENE. The pattern of bands obtained was designated the
ribopattern.
Examination of strains by electron microscopy
Some of the strains of H.pylori recovered from antral
biopsy and tooth plague were also examined by electron
microscopy. (This was done by Mr. F. Donnelly, Edinburgh).
For this, a rectangle of Skirrow's medium carrying a
dense growth of H.pylori from an antral biopsy or from
tooth pick plaque was cut from a culture plate and fixed
in 3% glutaraldehyde (Merck-Darmstadt Ltd)/0.1M sodium
cacodylate HCL (Merck, Darmstadt Ltd) buffer pH 7.2-7.4 for
45 minutes at 4-8° C and washed three times (each time for
10 minutes) gently in 0. 1M sodium cacodylate HCL buffer.
Post fixation (for lipids) was in 1% aqueous osmium
tetraoxide (Johnson Matthey) in 0.1M sodium cacodylate HCL
buffer for 30 minutes at 4-8° C in a fume cupboard. The
samples were washed three times (each time for 5 minutes)
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with deionised water. Thereafter the culture block was
dehydrated in gradually increasing concentrations of
ethanol (50%,70% and 90%) for 10 minutes in each. Three
exposures for 10 minutes in 100% ethanol finally dehydrated
the preparation. The culture block was submerged in a
linking agent (propylene oxide, Merck Darmstadt) three
times (each time for 10 minutes in fresh solution) and then
impregnated with araldite resin (Agar Scientific)
overnight. The culture block was then imbedded (with the
colonies face upwards) in freshly prepared resin and
"cured" for 48 hrs at 60° C. Sections 90 nm thick were cut
on an ultratome (Reichart 0M42) using a triangular glass
knife, picked up on 300 mesh copper grids, dried for 1 hr,
then stained with heavy metal salts (uranyl acetate with
lead citrate, Merck, Darmstadt) by Reynolf's method.
Sections were washed in deionised water and dried for 10
minutes before viewing in a JEOL 100 CXii (JEOL)
transmission microscope- operated at 60 KV. Photographs
were taken and processed using Ilford film, paper and
chemicals.
Histological examination
Standard paraffin sections prepared from endoscopic
antral biopsies were stained with haematoxylin and eosin,
or whenever necessary by Giemsa stain, and examined for the
presence of bacilli morphologically resembling H.pylori and
the presence of type B-gastritis.
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5.3.3 Statistical methods
DU and control patients were compared for presence of
binary factors after adjustment for age difference by
multiple logistic regression. Chi-squired test also used
for presence or absence of H.pylori in both groups.
5.4 RESULTS
Fifty nine (94%) of the patients with DU had
histologically demonstrable antral gastritis of varying
degree and in 53 (84%) the presence of H. pylori also
could be demonstrated histologically (table 5.1).
In the control group, seven (23%) had some form of
gastritis and H. pylori was seen in four (13%). H.pylori
was cultured from 56(89%) of 63 antral biopsies (fig. 5.1a)
and from samples of tooth plaque of 12(19%) patients with
DU (fig. 5.1b). In the controls, H.pylori was cultured from
the antral biopsies of four (13%) and from the tooth plaque
of two (7%) . H.pylori was not cultured from the dental
plates of three edentulous patients with DU nor from the
centrifuged saliva of any of the patients in either group.
The CLO test for urease was positive with the antral
biopsies in 50(79%) of the DU patients and from three (10%)
of the controls. Tooth plaque urease (CLO) tests were
positive in 19(57%) of 33 DU patients.
Electron microscopic examination showed that H.pylori
isolated from antrum (fig. 5.2a) and tooth plaque (fig.
5.2b) were similar.
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Table 5.1 Antral biopsies and tooth pick plaque
culture, urease test and histology of duodenal ulcer and
control (non-ulcer dyspepsia) group of patients.
Duodenal ulcer Control
group group
n=63 (%) n=30 (%)
Gastritis present
histologically 59 (94%)* 7 (23%)*
Helicobacter pylori
present histologically 53 (84%)** 4 (13%)**
Antral biopsy culture
positive 56 (89%)*** 4 (13%)***
Antral biopsy urease
(CLO) test positive 50 (79%)+ 3 (10%)+
Tooth pick plaque
culture positive 12 (19%) 2 (7%)
Tooth pick plaque urease n=33 (%)
(CLO) test positive 19 (57%)
= no experiments made
*; **; ***; + ; p<0.001
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Fig. 5.1 Light microscopic pictures of H.pylori
(total magnification 800)
a) Isolated from gastric antrum
b) Isolated from tooth plaque
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Fig. 5.2 Electron microscopic pictures of H.pylori
a) Isolated from gastric antrum
(total magnification 76108)
b) Isolated from tooth plaque
(total magnification 53568)
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In 12 DU patients, H.pylori was cultured from both the
gastric antrum and tooth plaque. No patient from this group
who was negative for H.pylori culture from the stomach had
H.pylori isolated from dental plaque (table 5.2).
In contrast, (table 5.3) only 2 control subjects were
found to have H.pylori isolated from both the gastric
antrum and tooth plaque. All control and ulcer patients who
were negative for H.pylori culture from plaque were also
negative for culture from the stomach.
In 48 DU patients, H.pylori was demonstrated
histologically and all of them had positive urease test.
Five patients had negative urease test though
histologically H.pylori was identified. One patient had
positive urease test but histologically H.pylori was not
identified (table 5.4).
In two control subjects, urease test was positive and
H.pylori was also demonstrated histologically. Two other
control subjects had negative urease test but H.pylori was
identified histologically. One subject had urease test
positive but histologically H.pylori was not identified
(table 5.5).
Relatedness of paired strains isolated from the mouth
and antrum of five patients were determined by ribotyping.
A mouth strain from a sixth patient was not analysed
because the antral strain did not survive for further
analysis. The identity of the five strains was confirmed as
H.pylori by DNA probing. Ribotyping showed that the oral
and antral isolates from each individual were identical.
The difference between the strains from patient C were
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minor and the strains were almost certainly the same (table
5.6) .
In figures 5.3a and 5.3b, 5.4 and 5.5 strains were
ordered according to patient (A-E); in each pair the first
specimen is from tooth plaque and the second one from
antrum. It was confirmed that pair strains of individual
are same by the following: rRNA gene patterns (ribopattern)
for Hae III and Hind III digest of genomic DNA from
H.pylori (fig. 5.3); Southern blots of Hae III digest probe
with a specific 16S rRNA gene probe obtained by polymerase
chain reaction (fig. 5.4); and recombinant DNA probe (HP7)
profiles of genomic Southern blots (Hind III digest) of
H.pylori which is specific for the organism (fig. 5.5).
Results of statistical analysis:
After adjustment for age, significant differences
(p<0.001) were found between DU and control patients for
presence of H.pylori in histology, antral biopsy culture
and antral biopsy urease test but the effect of tooth
plaque culture was not significant. Age did not differ
significantly between H.pylori positive and negative group
in tooth plaque culture or by urease test.
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Table 5.2 Comparative findings of antral biopsy and tooth
plague culture for H.pylori from duodenal ulcer patients.
Duodenal ulcer n=63
Tooth plaque Tooth plaque
culture positive culture negative
Antral biopsy
culture positive 12 45
Antral biopsy
culture negative 0 6
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Table 5.3 Comparative findings of antral biopsy and tooth
plaque culture for H.pylori from control subjects.
Control n=30
Tooth plaque Tooth plaque
culture positive culture negative
Antral biopsy
culture positive 2 3
Antral biopsy
culture negative 0 25
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Table 5.4 Comparative findings of histological presence












Table 5.5 Comparative findings of histological presence












Table 5.6 Ribotypes of H.pylori strains isolated and
their relation to each other.













Figure 5.3 The rRNA gene patterns (ribopattern) for a) Hae
III and b) Hind III digest of genomic DNA from H.pylori
are illustrated here. Size marker is Bst E II digest of
bacteriophage Lambda DNA. The strains were ordered
according to patient (A-E) and with each pair were arranged
by the site of isolation i.e.. first one from tooth plaque
and the second one from antrum. Strains isolated from each






Figure 5.4 The Southern blots of Hae III digest probe with
a specific 16S rRNA gene probe obtained by polymerase chain
reaction. Size marker is Bst E II digest of bacteriophage
Lambda DNA. The strains were ordered according to patients
(A-E) and within each pair were arranged by the site of
isolation i.e.. first one from the tooth plague and the
second one from antrum. Strains isolated from each patients










































Figure 5.5 Recombinant DNA probe (HP7) profiles of genomic
Southern blots (Hind III digests) of H.pylori are shown
above. This is H.pylori specific. Size marker is Bst E II
digest of bacteriophage Lambda DNA. The strains were
ordered according to patients (A-E) and within each pair
were arranged by the site of isolation i.e.. first one from
tooth plague and the second one from antrum. Strains
isolated from each patients were same except minor
variation in patients C.
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5.5 DISCUSSION
H.pylori is now accepted as a major contributor to the
development of chronic type B gastritis and subsequent
peptic ulcer formation in man; and eradication of H.pylori
from the stomach is an important requirement for long term
remission from peptic ulceration. It is still not clear
where the primary infection or re-infection originates. An
important start to such a study is a method which
unequivocally identifies H.pylori infection. Tests for
specific antibody have demonstrated that H. pylori is
widespread in the general population, the prevalence
increasing with age. The demonstration of the extracellular
enzyme activities of H.pylori, i.e.. urease , catalase and
oxidase, enables further identification, as do the
histological and electron microscopic appearances.
H.pylori Hindlll ribopatterns were used to
substantiate the identification of cultures of the organism.
Whilst lacking the absolute precision of DNA restriction
endonuclease digest patterns, the ribopatterns based on
rRNA gene restriction offer greater potential for typing
isolates of H.pylori. A wide range of different strains of
H. pylori have been identified in human infections with no
single strain being predominant in the aetiology of peptic
ulceration. A majority of H.pylori infected persons develop
DU, but many others do not. This might be due to host
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resistance, varying virulence of the organism or infection
with an ulcerogenic strain (Figura et al., 1989; Marshall,
1991).
In this study, antral biopsies from 94% of DU subjects
showed histological gastritis, 84% were H.pylori positive
on histological examination and 89% were positive for
H.pylori by culture. In contrast, the respective figures in
control subjects were 23%, 13% and 13%. All these
differences are statistically significant in relation to
age, supporting again the close association of H.pylori
with DU (Malfertheiner, 1988; Tytgat, 1989; Axon 1991).
There was no correlation found between age and H.pylori
positivity by any of the tests. To diagnose H.pylori
infection no single test is perfect (Megraud, 1988). In
this study H.pylori was shown to be present by culture or
histology in 89% and 84% respectively of DU patients. Thus
both tests equally reliably diagnose H.pylori infection, an
observation similar to that of Little et al. (1991).
H.pylori was cultured from tooth pickings in 12(19%) of
63 DU patients, and from 2(7%) of 30 control subjects. This
difference is not statistically significant. This may be
due to the different numbers of subjects in each group or
may reflect the common difficulty of isolating H.pylori in
the laboratory from culture plates carrying a heavy mixed
mouth flora.
It is possible that there is contamination of the oral
flora by antral contents containing H.pylori. The careful
separation of the endoscope from the teeth by the quite
large mouth guard, and the front piece of the guard over
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the teeth make the chances of such contamination very
remote. Furthermore the plaques were removed from teeth in
the anterior mouth which unlike saliva is not readily
contaminated. No organism was cultured from the mouth of
edentulous individuals.
The urease test carried out on tooth pickings was
positive in 19(57%) of samples from 33 DU patients.
H.pylori was isolated from tooth pickings from 5 of these
patients and from tooth pickings from 7 of 30 further DU
patients on whose tooth pickings urease tests were not
done. Urease tests were positive with antral biopsies from
79% of DU patients but from only 10% of control subjects.
This difference is statistically significant. In DU
patients, the antral biopsy urease test is positive almost
as often as histological examination or culture. As the
urease test is simple and cheap, it could be used for
preliminary screening, in the field. It is, therefore, a
sensible alternative to the other tests, especially in
developing countries where test costs are paramount and if
its cost can be minimised.
An important potential source for re-infection of the
stomach by H.pylori, might be the polymicrobial microaero-
bic environment of dental plaque or saliva. In this study
H.pylori was not grown from saliva. Krajden et al. (1989)
made a similar observation but were able to grow H.pylori
from the dental plaque of one patient out of a study group
of 71 patients with antral gastritis, 29 of whose antral
biopsies were culture-positive for H.pylori. Shames et al.
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(1989), in a complementary study to that of Krajden et al.
(1989), by using restriction endonuclease analysis with
HindiII, Haelll and Bglll endonucleases showed three
distinct strains of H.pylori in the mouth. Only one was
found in the antrum. Using a less precise identification
method, Desai et al., (1991) were able to demonstrate
CLO-test-positive organisms in both the antrum ( 83 % ) and
dental plaques ( 99 % ) of 43 patients with DU. Plaque was
obtained before endoscopic examination. Majumder et al.
(1990) isolated H.pylori from the dental plaque of all of
40 subjects ( endoscopy was not done in this study),
identifying it by urease tests, direct microscopy after
Warthin-Stary staining and by culture. All three tests
were positive in all 40 cases. The fact that two of the
five reports of successful culture of H.pylori from the
mouth are from a developing country (i.e.. India) might
simply reflect either the high prevalence of infection in
that population or the fact that it is not yet fashionable
to look for H.pylori in the mouth. Desai et al. (1991) were
able to eradicate H.pylori from the pyloric antrum, but
not from dental plaque using triple drug therapy consisting
of bismuth subcitrate, amoxycillin and metronidazole. This
is an important observation because it suggests that dental
plaque could be a persistent reservoir for antral re¬
infection and subsequent recurrent ulceration.
This is the first report from the United Kingdom of the
isolation of H.pylori from dental plaque. Among the pairs
of strains from six patients (from antrum and dental
plaque) the precision of the ribotyping was able
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unequivocally to relate mouth and antral strains to each
other. In four of five patients the strains were exactly
the same. The strains from patient C showed minor
differences and they were almost certainly virtually
identical. Normally the differences between each RNA
"house keeping geno-type" which were measured in this
methodology are very marked. Type la and lb is the presence
or absence of one or two minor bands which are possibly due
to one or two base substitutes. Otherwise la and lb are
same strain. The results also confirm the experiences of
others (Owen et al. , 1992b) i.e.. each patient would be
expected to carry a unique ribotype. Mouth carriage may be
more complex however; Shames et al., (1989), described
three distinct strains in dental plaque in one patient
but one only strain from the antrum.
Different individuals have been found to have the same
H.pylori strain if they live in the same household or have
very close contact with another household (Malaty et al.,
1991; Oderda et al., 1991; Vaira et al., 1991).
Subjects A and C carried similar DNA types they were
investigated at different times remote by several months
and had no contact with each other.
The mouth carries a heavy and extremely varied
microflora. Some bacteria might protect others against
harmful influences e.g., beta-lactamase producers can
protect benzylpenicillin from eradicating otherwise
penicillin-sensitive organisms such as Strep.pyogenes. A
similar mechanism might protect oral H.pylori from the
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effects of ampicillin so that they survive triple therapy
with bismuth subcitrate, amoxycillin, and metronidazole and
remain available for reinfection of the antrum.
Complete eradication of H.pylori from dental plaque
might be a prerequisite for successful long term remission
of peptic ulcer. Further studies should be undertaken to
confirm this proposition. It is not clear whether the mouth
colonises the stomach or the stomach the mouth. Nor is it
clear from where the original infection arises, though it
is evident that there is an enhanced risk of infection
from close contact grouping such as within families (Malaty
et al. , 1991; Oderda et al. , 1991; Vira et al. , 1991).
Recently, Thomas et al. (1992) have reported for the first
time the isolation of H.pylori from stool of 10 of 24
Gambian subjects. Faecal-oral transmission of H.pylori must
now be considered a strong possibility and this method of
transmission would explain much of the epidemiology of the
organism, particularly its increased prevalence in




PRESENCE OF H.pylori IN THE
MOUTH OF HOSPITAL INPATIENTS
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6.1 SUMMARY
The presence of H.pylori in the teeth of 100 dentulous
inpatients was sought by culture, the urease test and by
measuring H.pylori antibodies. From 30 edentulous
inpatients H.pylori antibodies was also measured. A
history of antibiotic therapy on admission or at any time
in preceding 3 to 6 months was recorded.
Elderly patients were more often seropositive than
younger subjects. Among dentulous patients tooth plaque
urease test positivity was significantly associated with
increasing H.pylori antibody titre ( p < 0.001). Urease
positivity was significantly correlated with age and
antibody titre in hepatic disease and ulcerative colitis. A




Having found H.pylori in the dental plaques of DU
patients, the presence of H. pylori in dental plaques of
hospital inpatients who had no evidence of DU was sought.
The effects of various antibiotic therapies upon H.pylori
in dental plaque were also examined.
6.3 MATERIALS AND METHODS
6.3.1 Subjects
One hundred patients, 55 males and 45 females, aged
from 15 to 86 years (mean 50 years) were studied. All were
patients in the gastrointestinal unit ward Western General
Hospital between October 1991 to May 1992. Each had at
least four adjacent remaining teeth. All were native born
Scots. Their presenting complaints or diagnosis, past
medical history, presence of DU or dyspepsia and history of
antibiotics therapy on admission or at any time in the
preceding 3-6 months were recorded.
Thirty edentulous subjects, 14 males and 16 females,
age ranged from 48 to 87 years (mean 70 years) were studied
as controls. All had attended the gastrointestinal unit,
Western General Hospital and all were native born Scots.
Their presenting complaints or diagnosis, past medical
history, presence of DU or dyspepsia and antibiotic
history were recorded using the same standard protocol.
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6.3.2 Methods
From 100 dentulous subjects teeth were scraped with a
plastic tooth pick ("Pick plak" HWC Supplies) and some
of the material recovered was used to inoculate a CLO test
strip to test for urease activity. A change of colour
from yellow to dark pink within 20 minutes to 3 hours
after inoculation would signify a positive test. The
remaining material was used to inoculate a plate of
Skirrow's medium within 15 to 30 minutes. This was
subsequently incubated for 4-6 days. Thereafter, colonies
morphologically resembling H.pylori were subcultured until
pure. The organisms were identified as H.pylori by i)
morphology in Gram's stained film; ii) positive tests for
urease activity; iii) positive test for catalase and
oxidase activity (Cowan and Steel, 1974).
A sample of blood was taken from both dentulous and
edentulous subjects; the serum was separated and stored
at - 7 0°C for subsequent testing for antibody to H.pylori.
6.3.3 Statistical methods
Age and antibody levels were compared in edentulous and
dentulous patients, urease positive and negative, by
Wilcoxon rank sum test. The antibody levels and age were
correlated using the Spearman correlation coefficient.
Multiple logistic regression was used to assess antibodies
in dentulous and edentulous patients, adjusted for age.
Kruskal-Wallis test was used to compare age and antibody
levels and chi-squared test for urease.
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6.4 RESULTS
Forty one (41%) of 100 dentulous inpatients and 16
(53%) of edentulous inpatients had antibody to H.pylori.
Tooth plaque urease (CLO) tests were positive in 30(30%) of
100 dentulous inpatients but H.pylori was isolated by tooth
plaque culture in only three (3%) of these (table 6.1).
Elderly patients had higher antibody levels whether
dentulous or edentulous (fig. 6.1 a and b).
Among the hundred dentulous inpatients (table 6.2), 28
had ulcerative colitis or some form of colonic disorder;
11 of these had antibody to H.pylori and nine had tooth
plaque urease (CLO) tests positive. Of 16 patients with
Crohn's disease, six had antibody to H.pylori and one was
tooth plaque urease test positive. H.pylori was cultured
from the tooth plaque of one of 16 patients admitted with
Crohn's disease. Of 27 patients admitted with liver disease
or for endoscopic retrograde cholangiopancreatography, 14
had antibody to H.pylori, 14 had positive tooth plaque
urease tests and H.pylori was cultured from the tooth
plaque of two. Of seven patients with chronic pancreatitis,
two had antibody to H.pylori and two had a positive urease
tests. Eleven patients had nonspecific abdominal pain; of
these three patients had antibody to H.pylori. Of six
patients with melaena, four had antibody to H.pylori and
three had a positive tooth plaque urease tests. 5 patients
had iron deficiency anaemia and malabsorption syndrome; of
these, one had antibody to H.pylori and another
133
Table 6.1 The presence of antibody to H.pylori in
inpatients with teeth and edentulous inpatients compared
with the results of tooth plague urease (CLO) tests and
culture in inpatients with teeth.
With teeth Edentulous
n = 100 n = 30
Test number (%) number (%)
Antibody present 41 (41)* 16 (53)*
Tooth plaque urease
(CLO) test positive 30 (30) -
Tooth plaque culture
positive for H. pylori 3 (3)
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Table 6.2 Disease pattern or diagnosis, related to the
presence of antibody to H.pylori, urease test results and




Antibody Tooth plaque Tooth plaque




























Total 100 41 30
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patient had a positive tooth plaque urease test.
The subsets shown in table 6.3 are too small to allow
any conclusions to be drawn about the relative prevalence
of H. pylori infection in these different disease states.
Antibiotics had no effect on H.pylori antibody status
whether dentulous or not. Among 5 CLO positive patients 3
had history of antibiotic consumption (table 6.4). The
commonly used antibiotic was amoxycillin (table 6.5) and
middle aged and elderly people consumed more antibiotics
(table 6.6).
Results of statistical analysis
Although antibody levels were significantly higher in
patients without teeth, this difference did not achieve
statistical significance when values were adjusted for age.
Among patients with teeth, a positive urease test was
significantly associated with age and antibody levels, both
at p< 0.001.
The diagnostic group (table 6.2) did not differ
significantly in either age or antibody levels, but did
show a difference (p< 0.05) in positive urease test, which
was more prevalent in those with hepatic disease and
ulcerative colitis.
6.5 DISCUSSION
Epidemiological studies suggest that H.pylori infection
increases with age both in developed and developing
countries. Studies of the prevalence of H.pylori infection
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Table 6.3 Disease pattern or diagnosis and presence of
antibody to H.pylori in 30 edentulous control inpatients.
Diagnosis on admission n Antibody to H. pylori
Ulcerative colitis and
other colonic disease 10 5
Crohn's disease 5 2
Hepatic disease 5 3
Oesophageal cancer 4 2




Deficiency anaemia 1 1
Total 30 16
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Table 6.4 Antibody to H.pylori in inpatients with teeth and
edentulous inpatients who had taken antibiotics related to




number (%) number (%)
Antibiotics taken 24 (24) 8 (27)
Antibody to H. pylori 8 (8) 2 (7)
Tooth plaque urease




Table 6.5 Antibiotics consumed and levels of antibody
titre (units/ml) in 100 inpatients with teeth.
n=loo
0-25 26-50 51-75 76-100 101-125
u/ml u/ml u/ml u/ml u/ml
No antibiotics
used 64 2 5 4 1
Amoxycillin 13 2 0 0 0
Tetracycline 400 1 0
Nitrofurantoin 100 0 0
Metronidazole 100 0 0
Gentimicin 010 0 0
Ampicillin and
metronidazole 100 0 0
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Table 6.6 Antibiotics consumed and age distribution of
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among hospital inpatients have not yet been reported. Many
hospitalised patients (up to 40% in some studies) take
antibiotics either singly or in combination before or
during their hospital stay (Chodak and Plaut, 1977).
Triple therapy (comprising bismuth subcitrate, and
metronidazole with amoxycillin or tetracycline) can
eradicate H.pylori from the stomachs of infected patients
(Rauws and Tytgat, 1990; Axon, 1991). Desai et al. (1991)
reported for the first time that while triple therapy
eradicated H.pylori from the stomach, the organism
persisted in dental plaque. At present it is difficult to
comment on whether systemic antibiotics affect mouth
carriage of H.pylori. The ease or otherwise of eradicating
H.pylori with antibiotic treatment from its proposed
reservoir of infection and reinfection in the mouth has
implications for reinfection of the stomach and recurrence
of DU.
A general ward population of patients with and without
teeth was studied by bacterial culture of tooth plaque, by
urease testing of tooth plaque and by measurement of plasma
H.pylori antibody. The 100 patients with teeth studied had
a mean age of 50 years while the 30 edentulous patients
had a mean age of 70 years. The age difference stems
directly from the presence or absence of teeth which were
used as the principal selection criterion.
Antibody to H.pylori was present in 41% and 53% of patients
with and without teeth respectively. This difference is not
statistically significant. Elderly patients had higher
antibody levels (fig. 6.1) and urease test positivity.
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Antibody levels were significantly higher in edentulous
patients but did not differ significantly after adjustment
of age for the presence or absence of teeth. Elderly
people were seropositive, a finding similar to other
epidemiological studies (Jones et al., 1986; Morris et al.,
1986b; Perez-Perez et al., 1988; Kosunen et al., 1989;
Megraud et al., 1989). Taylor and Blaser (1991) reported
that approximately half of all adults are colonised with
H.pylori by the age of 60 years in developed countries.
Jones et al. (1986) showed that in England 50% of those
over the age of 50 years have antibody to H.pylori. The
two latter findings are almost identical to those of the
present study. At present H.pylori infection is inversely
related to socioeconomic status in both developed and
developing countries (Al-Moagel et al., 1990; Taylor and
Blaser, 1991; Fiedorek et al., 1991; Sitas et al., 1991).
It is tempting to speculate that those born in the United
Kingdom or in developed countries in the first half of this
century had in general, poorer socioeconomic status than
those born later, thus explaining the higher percentage of
elderly people with H.pylori antibody.
H.pylori was cultured from tooth plaque of 3(3%) patients;
urease tests on tooth plaque were positive in 30(30%)
patients and H.pylori antibody was detected in 41(41%)
patients. The lower positivity by culture of tooth plaque
probably reflects the difficulty of growing the organism
and separating it from other microflora present in the
tooth plaque material. It is not surprising that these
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three tests gave different results. Culture of H.pylori is
demanding; organisms other than H.pylori can produce urease
and the presence of antibody relates as much to past as to
current infection, the defence mechanisms clearing H.pylori
but antibody persisting (Meyer et al., 1991). If the
present study protocol had included antral biopsy culture
in addition to tooth plague culture, urease test and
assessment of antibody status, stronger comments concerning
the relative value of these tests would have been possible.
Dooly et al. (1989) reported that culture of the antral
biopsy was positive in 19.4% of asymptomatic patients but
antibody to H.pylori was present in 33.7% of these. This is
similar to the urease test and serological findings of the
present study.
Of the 100 patients with teeth, antibody to H.pylori
was found more often in patients with hepatic disease who
have often been admitted for repeated endoscopic retrograde
cholangiopancreatography, patients with ulcerative colitis,
with Crohn's disease and in those admitted with haematemesis
or melaena. Hepatic disease and ulcerative colitis patients
had significant antibody levels and urease test positivity
in relation to their age. The reason for this distribution
is not clear. Langenberg et al. (1990) reported that
H.pylori has occasionally been transmitted from person to
person by improperly cleaned endoscopes. It is unlikely to
be the explanation in the present study because modern
endoscopic cleaning techniques are very stringent. In the
present study, systemic antibiotics given for whatever
reason had no effect on the rate of recovery of H.pylori
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from tooth plaque. Desai et al., (1991) reported similar
findings, i.e.; they were able to eradicate H.pylori from
the pyloric antrum but not from dental plaque by triple
therapy with bismuth subcitrate, amoxycillin / tetracycline
and metronidazole.
It is very difficult to comment on the effect of
antibiotic treatment on the presence of antibodies to
H.pylori, because antibodies were not measured before
antibiotic treatment started; however, antibody titres were
similar whether antibiotics had been taken or not.
To treat peptic ulcer disease and prevent its recurrence
it is probably necessary to eradicate H.pylori from the
mouth as well from the stomach. Whether this can be done by
high dose antibiotic therapy or local antiseptic dental
pastes is a matter of future study.
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CHAPTER 7
THE EFFECT OF BILE ACIDS
O N H.pylori GROWTH IN VITRO
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7.1 SUMMARY
H.pylori was cultured in the presence of sodium
taurocholate and human bile acids. No growth of H.pylori
was observed when higher concentrations of sodium
taurocholate (18mmol) and human bile acid (16mmol) were
added in Skirrow's medium. It is, therefore, possible
that H.pylori growth is suppressed or prevented in the
presence of high concentrations of either sodium
taurocholate or bile acids in vitro.
7.2 INTRODUCTION
H.pylori is not found in the stomach of patients with
reflux biliary gastritis (O'Connor et al., 1986a; O'Connor
et al., 1986b).
Biliary gastritis and Type B gastritis have a
different aetiology. Patients with these diseases may also
differ in regard to their H.pylori status and this could
be because of the effects of bile upon growth of the
organism. This was studied by culturing H. pylori in
the presence of bile acids.
7.3 MATERIALS AND METHODS
Sodium taurocholate (Sigma) was incorporated into
Skirrow's medium (Skirrow, 1977) in concentrations of 0,
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4, 6, 8, 10, 12, 14, 16, 18 and 20 mmol. A single strain of
H.pylori isolated from an antral biopsy was inoculated on
to each plate. The plates were examined for growth after
being incubated for 4-6 days at 37°C in 95-100% humidity
and an atmosphere containing nitrogen, oxygen and carbon
dioxide in ratios of 90:5:5. In a second series of
experiments a single sample of human bile was collected
after laparotomy and stored at -70° C. Within 15 days of
collection bile acid was measured (see below); and then it
was freeze-dried and its contained bile acids redissolved
into Skirrow's medium in concentrations of 0, 4, 6, 8, 10,
12, 14, 16, 18 and 20 mmol. A single strain (one loopful)
of H.pylori isolated from an antral biopsy but different
from that described above was inoculated on to each plate.
These plates were incubated and examined as above.
Only one strain of H.pylori was used in the experiment
due to the restricted availability of bile.
Measurement of bile acid concentration
Bile acid concentration was measured using the
Sterognost 3 alpha-pho kit for bile acid determination in
intestinal contents (Nycomed Ltd, Birmingham, UK). Bile (20
pi) was incubated for 15 minutes at room temperature with
1 ml test reagent containing 3-hydroxy-steroid
dehydrogenase and nicotinamide adenine dinucleotide (NAD),
and 0.25 ml methanol. NADH formed was measured at 340 nM in
a spectrophotometer (Pye Unicam Ltd, Cambridge, UK. 8610).
Blanks were set up omitting the enzyme reagent. A 2 mmol
sodium taurocholate solution was used as standard. Bile was
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measured with and without xlO dilution.
Test bile diluted 1 in 10 gave a mean optical density
340 nM of 0.263 which coresponded to 20.3 mmol/L on the
standard curve produced with sodium taurocholate; 2 mmol/L
standard gave a mean optical density 340 nM of 0.259.
Analysis was carried out in duplicate.
7.4 RESULTS
The H.pylori growth was confluent when cultured in
Skirrow's medium alone. When concentrations of 4 to 14
mmol of sodium taurocholate or human bile acids were added
in the Skirrow's medium the H.pylori grew in numerous
separate colonies. The growth of H.pylori was sparse when
16 mmol of sodium taurocholate was added, whereas no growth
was observed at the same concentration with human bile
acids; therefore, high concentrations of sodium
taurocholate or human bile acids suppressed or prevented
the growth of H.pylori in Skirrow's medium (table 7.1).
7.5 DISCUSSION
Bile acids have an adverse effect on the gastric
mucosa which may lead to biliary gastritis. H.pylori
infection is responsible for type B gastritis. The two
types of gastritis are thought to be distinct (O'Connor et
al., 1986a; Dixon et al., 1986).
In the present study, H.pylori was cultured in
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Table 7.1 Growth of H.pylori cultured on Skirrow's medium
with and without sodium-taurocholate or human bile acid.
Skirrow's With Na-tauro- With




8 mmol ++ ++
10,12 and
14 mmol ++ ++
16 mmol + NG
18 mmol NG NG
2 0 mmol NG NG
= No experiment made
NG = No growth of H.pylori
+++ = Confluent growth
++ = Numerous separate colonies
+ = sparse colonies of H.pylori.
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Skirrow's medium in the presence of either human bile acids
or Na-taurocho1ate. In the human bile duct, the
concentration of bile acids is 16 to 35 mmol/L. In the
presence of 16 mmol/L of Na-taurocholate or of 14 mmol/L of
human bile acid H.pylori grew sparsely; however, at higher
concentrations no growth of H.pylori was detected.
Normally intragastric bile acid concentration is less
than 1 mmol/L (Dixon et al. , 1986) and if duodenogastric
reflux occurs, concentration varies according to the
freguency and amount of bile refluxed. During
gastroduodenal reflux, concentrations of bile acids of the
order of 5 mmol/L have been measured (Dixon et al., 1986).
Bile acid concentration beneath the mucus layer is not
known although it is likely that this will be less than
intraluminal concentrations.
There are, therefore, reasons for suspecting that
H.pylori could exist in the stomach affected by biliary
gastritis. However, O'Connor et al. (1986b) and Lamers
et al. (1991) reported that patients who had had a Billroth
I or Billroth II partial gastrectomy or truncal vagotomy
and gastroenterostomy were significantly less likely to
carry H.pylori than those who had had highly selective
vagotomy or than controls. They suggested that reflux might
disrupt the mucus layer leading to the death of H.pylori
living beneath it, but did not identify the mechanism by
which bacterial death comes about.
The results of the present study show that refluxed
bile could not suppress the growth of H.pylori. It is
clear that in patients with Billroth I or Billroth II
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partial gastrectomy, truncal vagotomy and gastroenterostomy
bile reflux is greater and more freguently than occurs
often in highly selective vagotomy or gastrectomy with
Roux-en-Y anastomosis. O'Connor et al. (1989) also reported
that gastric remnants of patients with Roux-en-Y biliary
diversion may be colonised by H.pylori. In contrast,
Loffeld et al. (1988) reported that Campylobacter like




H.pylori AND GASTRIC CARCINOMA
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8.1 SUMMARY
Gastrectomy specimens obtained from 83 patients
undergoing gastrectomy for primary gastric cancer and 34
controls who underwent gastric surgery for peptic ulcer
were examined. The presence of H.pylori was determined
using H and E stains. Multiple sections uninvolved by
tumour or peptic ulcer were examined and the findings were
related to a range of histological abnormalities.
H.pylori was identified in 26(76%) of peptic ulcer
specimens. In contrast only 32(39%) gastrectomy specimens
from gastric cancer patients had evidence of H.pylori
(p<0.001). The presence of H.pylori was similar in tumours
of intestinal and diffuse type. Seventy three gastric
cancer patients had type B gastritis but only 27(37%) had
H.pylori. There was no significant correlation between the
presence of H.pylori and advancing age in intestinal type
and diffuse types of gastric cancer. There was no
significant association between the presence of H.pylori
and gastric intestinal metaplasia, tumour extent or stage.
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8.2 INTRODUCTION
A number of publications have suggested that H.pylori
infection predisposes to the development of gastric cancer.
These suggestions are not yet confirmed.
It is possible that chronic H.pylori infection might
lead to atrophic gastritis and gastric metaplasia. As
achlorhydria develops, H.pylori infection becomes less
because of the altered microenvironment within the stomach
and because of competition with other organisms which
colonise the stomach and may be involved in the formation
of carcinogenic chemicals. Cancer patients whose stomachs
exhibit type B gastritis may have different degrees of H.
pylori colonisation compared to patients with atrophic
gastritis or gastric metaplasia.
8.3 MATERIALS AND METHODS
8.3.1 Subjects
Specimens from 83 subjects with gastric cancer, 48
males and 35 females ranging in age from 35 to 89 years
(mean 69 years) , were studied. All had undergone
resectional surgery.
Peptic ulcer comparison group
Specimens from 34 subjects with peptic ulcer were studied.
They comprised 19 males and 15 females ranging in age from
25 to 87 years (mean 58 years). All had undergone
155
resectional surgery between 1986 - 1990 for benign disease,
principally gastric ulcer (in 31) or DU (in three).
8.3.2 Methods
The material studied consisted of tissue removed at
operation, fixed and subsequently stored in the Pathology
Department, Western General Hospital, Edinburgh. From the
different parts of each specimen six to 10 standard
paraffin sections were prepared and stained with
haematoxylin and eosin. In some cases, further sections
were stained with Giemsa stain. All were examined (by both
a specialist histopathologist and the author) for the
histological types of tumour present, for its stage and for
associated or other histological abnormalities, especially
gastritis and for the presence or absence of bacilli
morphologically resembling H.pylori.
The tumour stage was noted, and all tumours were typed
using the Lauren classification (Lauren, 1965).
The intestinal type of tumour was identified by the
presence of glandular differentiation, large cells with
abundant cytoplasm and hyperchromatic nuclei,
intracellular mucus polarised to cell apex and
extracellular mucous within gland lumen. This type of
tumour grows with an expanding or pushing margin.
The diffuse type of tumour was identified as tumour
cells in single or in small clumps, small cells with
inconspicuous cytoplasm and pyknotic nuclei; signet-ring
cells and extracellular mucus within the stroma were
common features. This type of tumour diffusely infiltrates
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to the adjacent area.
In addition, the presence and degree of gastritis in
the adjacent gastric mucosa was assessed. Where possible
this was assessed in both the body and antral mucosa. At
the same time the presence of significant intestinal
metaplasia was noted as indicating an atrophic gastritis.
Special stains for mucin were not used, the diagnosis
being based on haematoxylin and eosin stains only.
Semi-quantitative methods were used for the presence of
H.pylori (small number = + ; moderate quantity = ++ ;
numerous = +++).
8.3.3 Statistical methods
Statistical analysis of the results used the Wilcoxon
rank sum test for paired comparison for age and
histological presence of H.pylori in controls and in
patients of different groups of histological findings.
Multiple logistic regression was used to test for group
differences in histological presence of H.pylori adjusted
for age. Chi-squired test also used for histological
presence or absence of H.pylori.
8.4 RESULTS
The patients with the intestinal type of
adenocarcinoma were younger (mean age 66 years, range 35 to
87 years) than patients with diffuse type of adenocarcinoma
(mean age 71 years, range 52 to 89 years).
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In 32(39%) of the patients with gastric cancer there
was histological evidence of H.pylori infection in areas
not involved by tumour. By contrast 26 (76%) of the
control patients with peptic ulcer had evidence of
H.pylori (table 8.1). This difference is statistically
significant (p < 0.001).
In 83 patients with gastric cancer, 73(88%) had type
B gastritis, 48(58%) had intestinal metaplasia and/or
atrophic gastritis, 33(39%) had an intestinal type of
adenocarcinoma, 34(40%) had diffuse type of adenocarcinoma,
and 16(19%) indeterminate type of tumour (table 8.2).
Further analysis (table 8.3) the relationship between
H.pylori status, type B gastritis and gastric atrophy
showed relatively low proportion of specimens which were
non-atrophic with type B gastritis had histological
evidence of H.pylori (50%). In contrast, the majority of
those with gastric atrophy but without type B gastritis
were colonised with H.pylori (80%). The numbers are however
relatively small and statistical analysis is therefore
inapproripate.
Histologically H.pylori was seen in 27(37%) of patients
with gastritis (n=73), 16(33%) of patients with intestinal
metaplasia and or atrophic gastritis (n=48), 11(33%) of
patients with an intestinal type of adenocarcinoma (n=33),
15(44%) of patients with the diffuse type of adenocarcinoma
(n=34) and in 6(37%) of patients with indeterminate types
of tumour (n=16). None of these differences (p > 0.5) is
statistically significant even after adjustment for age.
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In the 34 control patients, H.pylori was present
significantly more often (p < 0.02) when type B gastritis
was present than if intestinal metaplasia or atrophic
gastritis were present (table 8.4).
In 50(60%) of the 83 patients with gastric cancer, the
tumour involved the full thickness of the stomach wall. In
33(40%), the involvement was superficial. H.pylori was
demonstrated histologically in 19(38%) of the former and
12(36%) of the latter.
Of 52 tumours (63% of the total) found in the body of the
stomach 20 were in the higher lesser curve, 5 in the
greater curve, 16 in the anterior or posterior wall or both
and 11 involved the whole of the stomach. Eight (9%) were
in the fundus or cardia, 20 (24%) in the gastric antrum,
1(1%) in the pylorus and 2(2%) in anastomotic sites.
In 32 patients with gastric cancer in whom H.pylori was
demonstrated histologically, the tumour was in the antrum
in 13(42%) and in the body of stomach in 29(94%).
Of 34 ulcer patients with peptic ulcer disease, the
ulcer involved the body of the stomach in 29 (85%). Of
these, 24(83%) had histological evidence of H.pylori. In
two (6%) of the control patients the ulcer was in the
gastric antrum and H.pylori was present in both on
histological examination. In three (9%) of the control
patients the ulcer was in the duodenum; in none of these
was there histological evidence of H.pylori.
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Table 8.1 Histological presence of H.pylori in patients
with gastric cancer and controls with benign disease.
n H.pylori positive(%)




Table 8.2 Additional histological findings in 83





Type B gastritis 73 27 (37)*
Atrophic gastritis and/
or intestinal metaplasia 48 16 (33)*
Intestinal type of
adenocarcinoma 33 11 (33)*
Diffuse type of
adenocarcinoma 34 15 (44)*
Indeterminate type
of tumour 16 6 (37)*
* p > 0.5. Not significant.
161
Table 8.3 H.pylori status in relation to the presence of
gastric atrophy and type B gastritis in 83 cancer patients.
H.pylori positive specimens
Atrophic No-atrophic
H.P +ve / total(%) H.P +ve / total(%)
Type B gastritis 12 / 43(28) 15 / 30(50)
No type B gastritis 4/5(80) 1/5(20)
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I
Table 8.4 Histological findings in 34 control patients




Type B gastritis 23 18 (78)*
Intestinal metaplasia and/
or atrophic gastritis 9 6 (67)*
* p < 0.02.
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Of 26 ulcer patients in whom H.pylori was demonstrated
histologically, the ulcer involved the gastric body in 18
(69%) and the antrum in 15(58%).
Small numbers of H.pylori were present in 10(56%) and
5(33%) of patients with an ulcer in the gastric body or
antrum respectively. H.pylori was numerous (+++) in 8(44%)
of the former and 10(67%) of latter.
Results of statistical analysis
H.pylori was significantly more common in gastrectomy
specimens from peptic ulcer than specimens from cancer
patients (p <0.001). There were no differences in the rate
of H.pylori positivity between intestinal and diffuse type
of cancer. Patients with the intestinal type of cancer and
ulcer patients did not differ significantly in age, but
those with the diffuse type of cancer were significantly
older than both of these groups (p< 0.05 and p< 0.01
respectively). After adjustment for age differences, both
the intestinal and diffuse cancer patients still differed
significantly (p<0.01) from that with ulcers in the
histological identification of H.pylori; but, there




The findings of this study do not support (but do
not contradict) a causal relationship between H.pylori
infection and gastric cancer. As expected, this organism
was usually present in stomachs resected for peptic ulcer;
the prevalence of infection was rather low in the cancer
cases and was similar to that expected for an age-matched
disease-free group of Western individuals (Graham et al.,
1991). H.pylori was not found more often in association
with tumours of intestinal than of diffuse type, nor was it
commonly found in association with intestinal metaplasia or
chronic gastritis. These conclusions are similar to those
reached by a group from Tokyo (Igarashi et al., 1992) who
could not find serological evidence linking H.pylori
infection and gastric cancer. Another Japanese group also
failed to show increased prevalence of H.pylori infection
in gastric cancer patients (Fukuda et al., 1992). A recent
study from Singapore (Wee et al., 1992) failed to show a
relationship between gastric tumour type and infection;
and, although H.pylori was commonly found in cancer
patients, the importance of this is unclear because a non-
cancer control group was not studied. An Italian group has
also failed to show any relationship between the presence
of H.pylori, chronic atrophic gastritis and gastric
metaplasia both of which are regarded as pre-malignant
entities (Testoni et al., 1992).
It is not clear why H.pylori and type B gastritis
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were not associated with intestinal metaplasia / atrophic
gastritis in the stomachs of some of the cancer patients.
These findings are similar to those of Igarashi et al.
(1992) and Testoni et al. (1992). One possible explanation
is that there is a patchy distribution of change.
Our data show much lower level of H.pylori in
association with type B gastritis than those normally been
recorded. Sub analysis showed that this was partly
atributable to the high prevalence of atrophy may diminish
H.pylori infection as the atrophy it induces progresses
(Sipponen, 1991). However, it may also reflect the
unreliability of routine reporting of H.pylori.
It is possible that pre-operative antibiotic therapy
prescribed to cancer patients could have eradicated
H.pylori or reduced the numbers of H.pylori. Questioning
the surgeons operating on the patients during this period
suggests that there was no pre-operative antibiotic policy
at that time. This makes the possibility less likely. The
results are more likely to be the consequences of gastric
atrophy accompanying the gastric cancer.
The findings of the present study and those of the
groups cited above are thus clearly at variance with other
publications which suggest that H.pylori infection
predisposes to the development of gastric cancer. For
example, it has been reported from China that the frequency
of gastric cancer correlates with the prevalence of
H.pylori antibodies (Forman et al., 1990). Other
populations with a high incidence of gastric cancer also
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have a high prevalence of these antibodies and infection
seems to be acquired at any early age in these individuals
(Fox et al. , 1989; Gastrointestinal physiology working
group, 1990). This association cannot be assumed to be
causal because other factors such as dietary habits, racial
differences and exposure to other carcinogens might also be
present in these high risk groups. Dooley (1991) suggested
that H.pylori might not cause gastric carcinoma, but
gastritis induced by the organism could act as the fertile
soil upon which other environmental variables come to bear.
Those who support a causal role for H.pylori infection
in the pathogenesis of gastric cancer suggest that chronic
infection with the organism leads to atrophic gastritis and
gastric metaplasia. As achlorhydria develops, H.pylori
infection becomes less because of the altered
microenvironment within the stomach and because of
competition with other organisms which colonise the stomach
and might be involved in the formation of carcinogenic
chemicals. The evidence that H.pylori gastritis leads to
atrophic gastritis is not compelling; and, in this study
and those of others (Testoni et al., 1992; Wee et al.,
1992), cancer patients whose stomachs did not exhibit
atrophic gastritis or gastric metaplasia had no higher
prevalence of H.pylori infection.
If H.pylori and gastric cancer were causally linked then
it would be reasonable to expect this to be particularly
true for the intestinal rather than diffuse type of tumour.
This study, as well as others (Wee et al., 1992; Nomura et
al., 1991), did not find this to be the case in contrast to
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the study reported by Parsonnet et al. (1991).
The reasons for these discrepancies in the
literature are not clear. Our study does not support a
causal relationship between H.pylori and gastric cancer,
but, because it is not prospective, does not provide
critical evidence against the hypothesis.
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CHAPTER 9
THE DEVELOPMENT OF A CHEAP
AND SENSITIVE UREA SOLUTION
FOR USE IN UREASE TESTS
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9.1 SUMMARY
An "in-house" urea solution was compared with the
commercially available urease (CLO) test. Three antral
biopsies were taken from 53 patients who were investigated
for upper gastrointestinal symptoms. One biopsy was
examined by histology; the others were subjected to urease
testing using CLO strips and the "in-house" urea solution.
The "in-house" urea solution was compared with the CLO test
using different bacterial dilutions and different buffer
concentrations.
The "in-house" urea solution gave faster positive




As commercially available kits for H.pylori urease
detection are too expensive for regular use in developing
countries, an alternative urea solution was developed.
A commercial kit for urease detection Campylobacter
pylori like organism (CLO) test and a freshly prepared
"in-house" urea solution were compared. Reactivity to
H.pylori urease was assessed in paired antral biopsies and
compared with histological findings.
9.3 MATERIALS AND METHODS
9.3.1 Urea solution
An "in-house" urea solution was prepared by dissolving
urea (Sigma) 2 g, phenol red (BDH) 0.05 g and sodium azide
(Sigma) 0.02 g in 100 ml of 0.01M phosphate buffer
(potassium di-hydrogen orthophosphate and di-sodium
hydrogen orthophosphate) adjusted to pH 6.5 (Hazell et al.,
1987) . From this solution, 50 pi was poured into the wells
of a microtitre tray (Flow Laboratory Inc) . Some further
experiments were performed in parallel in which urea was
dissolved in buffer solutions of 0.005M and 0.0025M
concentration, to determine if a reduction in buffer




Fifty three patients, all native born Scots, were
studied. There were 23 males and 30 females, ranging in age
from 14 to 84 years (mean 51 years); gastrointestinal
endoscopy was carried out in each as part of an
investigation of dyspepsia. Patients were excluded if they
had acute gastroduodenal haemorrhage, gastric surgery,
reflux oesophagitis or had taken drugs such as H2
receptor antagonists, antibiotics, bismuth subcitrate ("De-
Nol"), nonsteroidal anti-inflammatory drugs (NSAIDs),
steroids or anticoagulants at any time during the four
weeks before the study. At endoscopy, macroscopic findings
were documented and three pinch antral biopsies were
obtained from an area no further than 5 cms proximal to
the pylorus. Each biopsy was about 3 mm in diameter. One
was fixed in neutral buffered formalin for subseguent




The second biopsy was used in a CLO test for urease
activity. The third was inoculated to the freshly prepared
"in-house" urea solution in a microtitre tray well. This
was sealed with adhesive transparent tape. The time from
inoculation to a predetermined dark pink colour change was
measured and the optical density was then determined. This
was recorded and compared with the intensity of colour
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change and the time to achieve it in the CLO strip.
H.pylori was not quantified. A biopsy was considered to be
urease negative if a significant colour change did not
develop within 90 minutes. Uninoculated "in-house" urea
solution in an adjacent well served as a negative control.
In preliminary experiments the sensitivity of a CLO
strip and newly prepared "in-house" urea solution were
compared with a suspension of H.pylori. This was prepared
as follows. H.pylori was grown from an antral biopsy on
Skirrow's medium and incubated for 4 to 6 days at 37° C in
microaerophilic conditions with 95-100% humidity. One
colony from this growth was suspended in 2 ml of 0.9%
normal saline. Neither the bacterial count nor the
cloudiness of the suspension were recorded. The objective
of these experiments was to compare the new method with the
established CLO test rather than explore sensitivity in
terms of bacterial count. In a colony the average bacterial
count is usually 105 to 106. By dilution with normal
saline, four further suspensions, dilutions of 1 in 10, 1
in 20, 1 in 50 and 1 in 100 were prepared. From each of the
parent suspensions and the four dilutions, 25 jul were used
to test for urease activity in a CLO strip and in freshly
prepared "in-house" urea solution as described above.
At the same time and in the same way, the sensitivity
to urease of freshly prepared "in-house" urea solutions in
0.005M and 0.0025M phosphate buffer was determined.
Four sets of experiments were performed to allow
comparison of the CLO strip with the "in-house" urea
solution. The estimated time of positive reaction was the
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same in all experiments.
The sensitivity of the commercially available CLO test
is reported by the manufacturers by using an unspecified
bacterial load in antral biopsies as 65% positivity at 20
min, 80% at 40 min, 85% at 60 min and 95% at 180 min.
Maximum incubation period is 24 hours (Morris et al.,
1986a; Marshall et al., 1987).
9.3.4 Statistical methods
Chi-squared test was used for comparison between the urease
test and histological findings.
9.4 RESULTS
Both commercial and "in-house" urease tests
demonstrated H.pylori urease in 12(23%) of 53 antral
biopsies. Histological examination detected H.pylori in
16(30%) patients (table 9.1). These differences are not
statistically significant.
The sensitivity and specificity of the "in-house" urea
solution were 65.5% and 95% respectively. Positive and
negative predictive values were 83% and 85% respectively.
"In-house" urea solution gave positive results for
H.pylori urease activity with original bacterial suspension
and 1:10, 1:20, 1:50 and 1:100 dilutions of it in 20, 25,
35, 48 and 60 minutes respectively. By contrast the
commercial CLO test exposed to the same bacterial dilutions
gave positive results in 20, 28, 45, 60 and 90 minutes
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respectively, i.e.. the "in-house" urea solution
consistently gave faster results (table 9.2 and fig. 9.1).
Table 9.3 and fig. 9.2 show that lowering the buffer
concentration speeds the already quick development of a
positive test for urease in the "in-house" urea solution.
Results of statistical analysis
There were no significant differences in the
sensitivity of urease test and histological findings
(table 9.1).
9.5 DISCUSSION
To fulfil the need for a simpler, faster and cheaper
way of diagnosing H.pylori infection, several modifications
of the urease test have been attempted (McNulty, 1989). The
specificity of this test is satisfactory though the
sensitivity varies.
The sensitivity depends upon elapsed test time, size
of biopsy, concentration of urea, phenol red (pH
indicator), buffer in the gel or solution and temperature
(Marshall et al., 1987; McNulty, 1989). Sensitivity might
also depend on the viability of the organisms and urease
activity (Chodos et al., 1988). Hazell et al. (1987) found
75% sensitivity within one hour, reaching 91% within 18
hours. The positive and negative predictive values were 96%
and 73% respectively. Vaira et al. (1988a) found positive
results in 62% of cases compared with other tests and
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Table 9.1 Comparative detection of H.pylori in gastric
antral biopsies by (a) urease demonstrated by commercial
CLO test, (b) urease demonstrated by "in-house" urea










Table 9.2 Comparison of the reactivity of "in-house"
urea solution and commercial CLO test with different































1st dil. 1:10 1:20
Dilution
1:60 1:100
—\~ Urea solution -Q- CLO atrip
Fig. 9.1 Compariaon of reactivity of "in-houae* urea aoiution
and CLO teat with different diiutiona of H.pylori auapenaion
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Table 9.3 The effects of phosphate buffer strength on
the demonstration of H.pylori urease.
Strength Time (min) to a positive "in-house" urease
of H.pylori test with phosphate buffer of strength:
suspension 0.01M 0.005M 0.0025M
Original suspension 20 16 12
1:10 dilution 25 20 17
1:20 dilution 35 30 26
1:50 dilution 48 44 39
1:100 dilution 60 56 51
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+ 0.01M 0.005M "O- 0.0025M
Fig. 9.2 Effects of phosphate buffer
strength on the demonstration of
H.pylori urease
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Coudron and Kirby (1989) found 62% sensitivity. Megraud
(1988) stated that compared with other tests, the urease
test is insensitive, but specific, rapid, very simple
and the cheapest way of diagnosing H.pylori infection.
In the present study, three antral biopsies from each
of 53 patients were tested for the presence of H.pylori by
histology and by two urease tests, one made with a
commercial CLO strip and the second with the freshly
prepared "in-house" urea solution. After 90 minutes,
positive results were identical in both tests. The
sensitivity and specificity (compared to histology) were
65.5% and 95% respectively and positive and negative
predictive values were 83% and 85% respectively.
The slightly lower sensitivity of the urease test made
with "in-house" urea solution in the present study might be
due to the elapsed time (90 min), the temperature of the
endoscopy room (30° C) , the fact that uncrushed biopsy
material was used or small numbers of organisms present in
the particular biopsies which were used.
Though sensitivity can be affected by several
variables, it must ultimately depend on the number of
organisms present in each biopsy (Marshall et al., 1987).
To compare the sensitivity of the "in-house" urea
solution with the commercial CLO urease test, bacterial
suspensions of gradually increasing dilution of the
original suspension were used (table 9.2 and fig. 9.1).
With each dilution of bacterial suspension, the "in-house"
urea solution gave a faster result than the commercial CLO
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urease test. With the greatest dilution of bacteria tested
(1:100,= 500 - 5,000 bacteria) the time required to produce
positive results was 30 minutes less with the "in- house"
urea solution than with the commercial CLO urease test.
Dilution of the "in-house" urea solution more than
1:100 was not tested because it was felt that very dilute
solution might be unstable and time taken for a positive
result would be unacceptably long.
Vaira et al. (1988b) described a rapid urease test
using 6% urea and reading at one minute. Arvind et al.
(1988) used 10% urea and 1% phenol red. In these tests
buffer was not used, although Vaira et al. stated that a
minimum concentration of buffer is needed to stabilise the
test and improve its shelf-life.
In the present study, to improve the sensitivity of the
test and to reduce its cost compared with the commercial
CLO test, the buffer concentration was reduced. Table 9.3
and fig. 9.2 shows that lowering the concentration of
buffer produced faster positive results even with gradually
reducing bacterial numbers e.g., at (1:100) dilution with
0.0025M buffer, a positive result appeared 9 minutes
earlier than with 0.01M buffer.
Each commercial CLO urease test costs one pound
sterling. The "in-house" urea solution prepared in this
study cost at most 10 pence for each test. McNulty (1989)
has also found that an "in-house" test with 2% urea broth
was cheaper costing only 5 pence for each test compared
with two pounds sterling for each commercially produced
test.
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In spite of all the advantages of the urease test,
there is some lack of concordance when it is compared with
other tests, possibly due to sampling variation (Mobley et
al., 1988). H.pylori infection can be patchy, the organism
being present in one specimen but not others; however the
in vitro studies suggest that as few as 500 bacteria might
be detected. As might be expected, the urease test is less
sensitive in patients who have received antimicrobial drugs
or bismuth treatment (Deltenre et al., 1989).
As a field test, especially in developing countries
where the cost of investigation is a major problem for
diagnosis, the "in-house" urea preparation will help to





The work reported in this thesis has addressed aspects
of the role of H.pylori in gastroduodenal disease.
The relationship between linoleic acid consumption,
peptic ulcer, smoking and H.pylori status was explored in
chapters 3 and 4. Previous workers had suggested that low
adipose percentage linoleic acid in DU was a consequence of
low dietary intake but as discussed in the chapters
mentioned; the finding of normal intake refuted this
hypothesis. Individuals who smoked also exhibited low
adipose percentage linoleic acid, despite a normal intake.
This suggests abnormal linoleic acid metabolism in smokers
and DU patients and it is tempting to speculate that this
might in some way represent a mechanism by which smoking
predisposes to DU. There was, however, no additive or
synergestic effect in smokers with DU. Conceivably,
abnormal PG metabolism is a consequence of smoking and this
accentuates an ulcer diathesis. Other possible explanations
including linoleic acid malabsorption seem unlikely. The
relationship between low percentage linoleic acid in
adipose tissue and H.pylori status is difficult to
establish because H.pylori and DU are so strongly linked.
It is conceivable that abnormalities in the
microenvironment of the mucus layer are created by
underlying alterations in linoleic acid and PG metabolism
and this facilitates H.pylori colonisation. The experiments
described in this thesis are unable to take this
possibility further.
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Whether it is possible to modulate linoleic acid and PG
metabolism, thereby alleviating the DU tendency, is not
clear. Workers have shown that increased dietary linoleic
acid intake enhanced gastric PG output; but it is not known
whether this affects either H.pylori status or the natural
history of peptic ulcer disease.
The work in chapter 5 describes the isolation of
strains of H.pylori from the mouth and antrum of DU
patients. The similarity of these strains was determined by
ribotyping, the most discriminatory typing method for
H.pylori currently available. Not surprisingly, the strains
from the mouth and stomach are indistinguishable. This
supports the hypothesis that a reservoir of H.pylori for
re-infection of the stomach lies in the mouth. The methods
used in endoscopy make contamination from stomach unlikely,
but does not eliminate this possibility.
It is now clear that DU can be successfully treated
with antibiotics by eradicating H.pylori from the stomach
but relapse is associated with re-infection. Whether triple
therapy eliminates H.pylori from dental plaque is unclear,
but if not, this might be a mechanism for re-infection of
the stomach. This point should be clarified by further
investigation, and it may be necessary to devise specific
means to eliminate H.pylori from the mouth.
Chapter 6 describes the prevalence of serum antibody to
H.pylori, and the presence of H.pylori in the mouth of
hospital inpatients. This is the first time such a study
has been reported in the UK. It confirms that
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seropositivity and tooth plaque urease test increases with
age - a result possibly due to poorer socio-economic
conditions in the UK during the first half of this century
or a phenomenon due to less emphasis upon oral hygeine
during this period. Antibiotic therapy did not influence
the prevalence of oral H.pylori. This suggests that triple
therapy only eradicates infection in the antrum, leaving a
nidus for re-infection in the mouth.
It has also been shown at a statistically significant
level, that patients with hepatic disease and ulcerative
colitis are more likely to have antibody titres to
H.pylori and positive urease test. The reasons for this are
not clear. Such patients are either more likely to be
exposed to infection or less able to resist infection when
exposed in the general population. Current knowledge does
not allow further speculation.
The experiments described in chapter 7 show that
concentrations of bile acid likely to be present in the
stomach subjected to biliary reflux do not inhibit
H.pylori in vitro. However, it is now recognised that
H.pylori is infrequently found in the presence of biliary
gastritis.
The work recorded in chapter 8 failed to show any
direct connection between the presence of H.pylori in the
stomach and the development of gastric cancer. This does
not support the hypothesis that gastric cancer and H.pylori
gastritis are associated, although the data do not refute
the possibility. This adds to the body of evidence that, if
H.pylori is linked to malignant disease of the stomach,
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the link is an indirect one. If it is true that gastritis
induced by H.pylori prepares the way for other carcinogenic
influences to act (Dooley, 1991), eradication of H.pylori
from the stomach and the mouth should lead to a reduced
incidence of gastric carcinoma.
Given the extent and significance of H.pylori
infection, rapid and cheap methods for its recognition are
important. The urease test is widely used to identify the
presence of H.pylori but the commercial kit is relatively
expensive. Chapter 9 describes the preparation of a cheap
alternative which is satisfactorily sensitive and specific
and could be of great value for epidemiological studies in
developing countries. Whilst the limits of sensitivity were
not defined, the range of sensitivity is the same as the
commercial kits. These results fulfil the requirements
originally defined.
H.pylori infection is probably one of the common
bacterial infection of man, but its reservoir and mode of
transmission have not yet been clearly established. If the
usual pattern of investigation of a newly discovered
infection is followed in this case, research to produce an
effective vaccine should develop in the near future.
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SUGGESTIONS FOR FUTURE WORK
(1) Modification of linoleic acid levels by dietary
manipulation to define effects upon gastric H.pylori status
and the natural history of DU.
(2) Eradication of H.pylori from dental plaque using
local or systemic means to determine the natural history of
gastric re-infection by H.pylori following triple therapy.
(3) A longterm prospective study of H.pylori status by
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APPENDIX
An example of a dietary diary.
Names and addresses of suppliers of
chemicals and equipment referred to.
Guidelines for diet history
Please record all food and drinks eaten over a 7 day period. The
following guidelines will help you to give an accurate acount of
your diet.
1. Describe the type of food eg milk if skimmed, seni-skimmed
full fat.
2. Indicate the amount of food. If unable to give a weight use
household measures eg tablespoon, teaspoon, cups etc.
3. State cooking methods used eg fried, grilled or baked.
4. Foods not eaten regularly. Indicate where possible the
number of times eaten per week and the quantity.
5. Remember to indicate drinks and any sugar or mixers added to
them.
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Names and addresses of suppliers of chemicals and equipment
referred to.
1. Agar Scientific Ltd., 66a Cambridge road, Stansted,
Essex, UK.
2. Baxter Health Care Ltd., Thorpe Lea Manor, Egham,
Surrey, UK.
3. BDH Ltd., Bruntfield Avenue, Thornly Bank, Glasgow, UK.
4. Delta West Ltd., 15 Bridie Hall Drive, Bentely, Western
Australia.
5. Denley Instruments Ltd., Natts Lane, Billingshurst,
West Sussex, UK
6. Dynatech Laboratories Ltd., Daux Road, Billingshurst,
West Sussex, UK.
7. Flow Laboratories Ltd., Wood Cock Hill, Harefield Road,
Rickmansworth, Hert, UK.
8. Gibco Life Technology Ltd., P.O. Box 36, Trident House,
Renfrew Road, Paisley, Glasgow, UK.
9. HWC Supplies, 94 Priory Road, Cheam, Surrey, UK.
10. Jeol(UK) Ltd.,Jeol House, Silver Court, Watchmead,
Welwyn Garden City, Hertfordshire, UK.
11. Johnson Matthey Ltd., Orchard Road, Royston,
Hertfordshire, UK.
12. Lab System UK Group Ltd.,Unit 5, The Ringway Centre,
Edison Road, Basingstoke, Hants, UK.
13. Merck-Darmstadt Ltd., Bruntfield Avenue, Thornly Bank.
Glasgow, UK.
14. Prolab Diagnostic, 10a Croft Business Park,
Bromborough, Wirral, Merseyside, UK.
15. Proton Cambridge, Proton House, Vanwall Road,
Maidenhead, Berkshire, UK.
16. Rathburn Chemical, Caberston Road, Walkerburn,
Peebleshire, UK.
17. Scottish Biotechnology Instrumentation, Blairgowrie
Business Centre, 60 High Street, Blairgowrie, Perthshire,
UK.
18. Sigma Chemical Co Ltd., Fancy Road, Poole, Dorset, UK.
19. Supelchem Co UK Ltd., Shire Hill, Saffron Walden,
Essex, UK.
